Protocol I1F-MC-RHBQ
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus 
Placebo in Patients with Moderate-to-Severe Genital Psoriasis
[STUDY_ID_REMOVED]
Approval Date: 14-Nov-2015
I1F-MC-RHBQ Clinical Protocol Page 1
LY2439821Protocol I1F-MC-RHBQ
A Multicenter, Randomized, Double -Blind Study  Comparing 
the Efficacy  and Safety  of Ixekizumab Versus Placebo in 
Patients with Moderate -to-Severe Genital Psoriasis
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to person s not involved in the clinical investigation of 
ixekizumab (LY2439821), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries .  
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure .  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release .  In 
the United States, this document is subject to Freedom of In formation Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
ixekizumab (LY2439821)
Study I1F -MC-RHBQ is a Phase 3, multic enter, randomized, double -blind, pl acebo-
controlled, parallel -group, outpatient study examining the efficacy and safety of ixekizumab 
80mg Q2W  (subcutaneous [SC] ) as compared to placebo SC in patients with moderate -to-
severe genital psoriasis, during a double -blind, 12 -week Blinded Treatment Period followed 
by a 40 -week Open -Label Treatment Period .
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly on date provided below.
Approval Date: 14-Nov-2015 GMT
I1F-MC-RHBQ Clinical Protocol Page 2
LY2439821Table of Contents
Section Page
1. Protocol  Synopsi s................................................................................................................ 9
2. Introduction ...................................................................................................................... 12
2.1. Background .................................................................................................................. 12
2.2. Study  Rati onale ............................................................................................................ 13
3. Objec tives and Endpo ints.................................................................................................. 15
4. Study  Design ..................................................................................................................... 19
4.1. Overview of Study  Design ........................................................................................... 19
4.2. End of Trial Definit ion.................................................................................................22
4.3. Scientific Rationale for Study  Design ........................................................................... 22
4.4. Justification for Dose ................................................................................................... 22
4.5. Benefit/Risk Assessment .............................................................................................. 23
5. Study  Popul ation............................................................................................................... 24
5.1. Inclusio n Cri teria.......................................................................................................... 24
5.2. Exclusio n Cri teria........................................................................................................ 25
5.3. Screen Failures ............................................................................................................. 30
5.4. Lifest yle and/or Dietary Requirements ......................................................................... 30
6. Treatment .......................................................................................................................... 31
6.1. Treatments Administered ............................................................................................. 31
6.2. Method of Treatment Assignment ................................................................................ 34
6.2.1. Selection and Timing o f Doses ............................................................................. 34
6.3. Blinding ....................................................................................................................... 34
6.4. Packaging and Labelling .............................................................................................. 35
6.5. Preparati on/Handling/Storage ....................................................................................... 35
6.6. Dose Modificat ion........................................................................................................ 35
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 35
6.7. Treatment Compliance .................................................................................................37
6.8. Concomitant Therapy ................................................................................................... 37
6.9. Treatment after Study  Com pletion................................................................................ 41
6.9.1. Continued Access .................................................................................................41
7. Discontinuati on Cri teria .................................................................................................... 42
7.1. Discontinuati on from Study  Treatm ent......................................................................... 42
7.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 42
7.1.2. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 44
7.1.3. Perm anent Discont inuat ion from the Study .......................................................... 44
I1F-MC-RHBQ Clinical Protocol Page 3
LY24398217.1.4. Patients Lost to Follow -Up................................................................................... 44
8. Study  Assessments and Procedures ................................................................................... 45
8.1. Efficacy Assessments ................................................................................................... 45
8.1.1. Primary Efficacy  Assessments ............................................................................. 45
8.1.1.1. Static Physician Global Assessment of Genitalia ............................................ 45
8.1.2. Secondary  Efficacy  Assessments .......................................................................... 45
8.1.2.1. Clinician Reported Assessments ..................................................................... 45
8.1.2.1.1. Modified Genital Psoriasis Area and Severit y Index.................................45
8.1.2.1.2. (Overall) static Physician Glo bal Assessment ............................................ 46
8.1.2.2. Patient Reported Assessments ......................................................................... 46
8.1.2.2.1. Genital Psoriasis Symptoms Scale ............................................................ 46
8.1.2.2.2. Genital Psoriasis Sexual  Impact Scal e....................................................... 46
8.1.2.2.3. Sexual Frequency  Questi onnai re............................................................... 47
8.1.2.2.4. Patient’s Gl obal Assessment of Genital Psoriasis ...................................... 48
8.1.2.2.5. Derm atology Life Qualit y Index............................................................... 48
8.1.2.2.6. Medical Outcomes Study  36-Item Short -Form  Heal th 
Survey ...................................................................................................... 48
8.1.3. Exploratory  Efficacy  Assessments ....................................................................... 48
8.1.3.1. Clinician Reported Assessments ..................................................................... 48
8.1.3.1.1. (Overall) Psoriasis Area and Severit y Index.............................................. 48
8.1.3.1.2. Percentage of Body  Surf ace Area .............................................................. 49
8.1.3.1.3. Fitzpatrick Skin Ty pe Assessment ............................................................ 49
8.1.3.1.4. Binary Quest ions on Psoriasis Location .................................................... 49
8.1.3.1.4.1. Overall ................................................................................................ 49
8.1.3.1.4.2. Genital ................................................................................................ 49
8.1.3 .1.5. Binary Quest ions on Characterist ics.......................................................... 49
8.1.3.1.5.1. Genital ................................................................................................ 49
8.1.3.1.5.2. Perianal/Gluteal  Cleft .......................................................................... 49
8.1.3.2. Combined Clinician/Pat ient Reported Assessment .......................................... 50
8.1.3.2.1. Com prehensive Assessment of the Psoriasis Pat ient.................................. 50
8.1.3.3. Patient Reported Assessment .......................................................................... 50
8.1.3.3.1. Touch Avo idance Numeric Rat ing Scale ................................................... 50
8.1.4. Appropriateness of Assessments .......................................................................... 50
8.1.4.1. Static Physician Global Assessment of Genitalia ............................................ 50
8.1.4.2. Modified Genital Psoriasis Area and Severit y Index....................................... 50
8.2. Adverse Events ............................................................................................................ 51
8.2.1. Serious Adverse Events ........................................................................................ 52
8.2.2. Adverse Events of Special Interest ....................................................................... 53
I1F-MC-RHBQ Clinical Protocol Page 4
LY24398218.2.2.1. Suspected Unexpected Serious Adverse React ions.......................................... 53
8.2.3. Com plaint Handling ............................................................................................. 54
8.3. Treatment of Overdose .................................................................................................54
8.4. Safety Assessments ...................................................................................................... 54
8.4.1. Electrocardiograms .............................................................................................. 54
8.4.2. Vital Signs ........................................................................................................... 54
8.4.3. Laboratory  Tests .................................................................................................. 54
8.4.4. Physical Examinat ion........................................................................................... 55
8.4.5. Chest X -Ray and Tuberculosis Test ing.................................................................55
8.4.6. Immunogenicit y................................................................................................... 56
8.4.7. Quick Inventory  of Depressive Symptom atology—Self -
Report (16 Items) ................................................................................................
.56
8.4.8. Safety Moni toring ................................................................................................ 57
8.4.8.1. Neutropenia .................................................................................................... 57
8.4.8.2. Hepati tis B Monitoring ................................................................................... 59
8.4.8.3. Hypertensio n.................................................................................................. 59
8.5. Pharmacokinet ics......................................................................................................... 59
8.6. Pharmacodynamics ...................................................................................................... 60
8.7. Genet ics....................................................................................................................... 60
8.8. Biomarkers ................................................................................................................... 61
8.8.1. Samples for Immunogenicit y Research .................................................................61
8.8.2. Samples for Genital Candida Testing ................................................................... 61
8.9. Heal th Economics ........................................................................................................ 62
9. Statistical Considerations and Data Analysis ..................................................................... 63
9.1. Determinat ion of Sample Size ...................................................................................... 63
9.2. General Statist ical Considerat ions................................................................................ 63
9.3. Analysis Populat ion..................................................................................................... 64
9.3.1. Missing Data Imputation ...................................................................................... 64
9.3.2. Adjustment for Mul tiple Com parisons .................................................................. 65
9.4. Treatment Group Comparabilit y................................................................................... 65
9.4.1. Patient Disposi tion............................................................................................... 65
9.4.2. Patient Characteri stics.......................................................................................... 65
9.4.3. Concomitant Therapy ........................................................................................... 66
9.4.4. Treatment Compliance ......................................................................................... 66
9.5. Primary and Secondary  Analyses ................................................................................. 66
9.5.1. Primary Analyses .................................................................................................66
9.5.2. Secondary  Analyses ............................................................................................. 67
9.5.3. Exploratory  Analyses ........................................................................................... 67
I1F-MC-RHBQ Clinical Protocol Page 5
LY24398219.6. Safety Analyses ............................................................................................................ 67
9.6.1. Adverse Events .................................................................................................... 67
9.6.2. Clinical Laboratory  Tests ..................................................................................... 68
9.6.3. Vital Signs, Physical Findings, and Other Safet y Evaluat ions............................... 68
9.7. Pharmacokinet ic/Pharmacodynamic Analyses .............................................................. 69
9.8. Other Analyses ............................................................................................................. 69
9.8.1. Subgroup Analyses .............................................................................................. 69
9.8.2. Immunogenicit y Analyses .................................................................................... 70
9.9. Interim Analyses .......................................................................................................... 70
10. Study  Governance Considerat ions..................................................................................... 71
10.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 71
10.1.1. Inform ed Consent .................................................................................................71
10.1.2. Ethical Review ..................................................................................................... 71
10.1.3. Regulatory  Considerat ions................................................................................... 71
10.1.4. Invest igator Informat ion....................................................................................... 72
10.1.5. Protocol  Signatures .............................................................................................. 72
10.1.6. Final Report Signature ......................................................................................... 72
10.2. Data Qualit y Assurance ................................................................................................ 72
10.2.1. Data Capture System ............................................................................................ 73
10.3. Study  and Si te Cl osure .................................................................................................73
10.3.1. Discontinuati on of  Study  Sites............................................................................. 73
10.3.2. Discontinuati on of  the Study ................................................................................ 74
11. References ........................................................................................................................ 75
I1F-MC-RHBQ Clinical Protocol Page 6
LY2439821List of Tables
Table Page
Table RHBQ.3.1. Object ives and Endpo ints............................................................................... 15
Table RHBQ.6 .1.Treatment Regimens ...................................................................................... 33
Table RHBQ.6.2. Concomitant Medication Permitted/Not Permitted in the Study ..................... 38
I1F-MC-RHBQ Clinical Protocol Page 7
LY2439821List of Figures
Figure Page
Figure RHBQ.4.1. Illustrati on of  study  design for Clinical Protocol I1F-MC-RHBQ. ............. 21
I1F-MC-RHBQ Clinical Protocol Page 8
LY2439821List of A ppendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 79
Appendix 2. Schedule of Act ivities.................................................................................... 83
Appendix 3. Clinical Laboratory  Tests ............................................................................... 93
Appendix 4. Hepati c Moni toring Tes ts for Treatment -Emergent Abnormalit y.................... 95
I1F-MC-RHBQ Clinical Protocol Page 9
LY24398211.Protocol Synopsis
Title of Study:
A Multicenter, Randomized, Double -Blind Study  Comparing the Efficacy and Safety of Ixekizumab Versus Placebo 
in Patients with Moderate -to-Severe Genital Psoriasis
Rationale :  
Approximately 29% to 63% of patients with chronic plaque psoriasis are impacted by psoriatic lesions in the genital 
area at some point during the course of the dis ease (Fouéré et al. 2005; Meeuwis et al. 2010, 2011a; Ryan et al. 
2015). When compared to psoriasis patients without genital involvement, quality of life was found to be 
significantly worse in patients with genital lesions (Meeuwis et al. 2011b ; Ryan et a l. 2015 ). Itch and sexual 
impairment have been reported as key bothersome issues for patients with genital psoriasis (Meeuwis et al. 2015; 
Ryan et al. 2015). Despite the significant impact on quality of life and sexual health, genital psoriasis is neithe r 
frequently discussed by patients (AAD Work Group et al. 2011; Meeuwis et al. 2012; Andreassi and Bilenchi 2014) 
nor routinely questioned or examined by health care professionals (Farber and Nall 1992; AAD Work Group et al. 
2011).
Although genital psorias is appears to be pathophysiologically identical to plaque psoriasis in other skin regions, the 
skin in this area is highly sensitive and at increased risk of adverse reactions to topical treatments (CDA 2009 
[WWW]; Meeuwis et al. 2011a; Guglielmetti et al. 2012). Specifically, available topical agents may not offer the 
optimal o r even appropriate level of clinical improvement or tolerability, especially for patients with moderate -to-
severe genital psoriasis.
Currently , there are limited data from clinical trials, particularly well -controlled therapeutic interventional studies, 
which measure the efficacy of treatments for genital psoriasis. To date, the only published treatment studies of 
genital psoriasis include open -label studies of topical treatments (J emec and Baadsgaard 1993; Rallis et al. 2005; 
Martín Ezquerra et al. 2006; Bissonnette et al. 2008), a recent open -label study of a stepwise treatment algorithm 
(Meeuwis et al. 2015), and scattered case reports. Based on the Phase 3 psoriasis clinical trialoutco mes,
ixekizuma b therapy in patients with moderate -to-severe genitalpsoriasiscouldaddress an unmet patient need and a
clinical research gap identified by the dermato logycommun ity and the American Academy of Dermatology Psoriasis 
Guidelines of Care Working Group (Ryan et al. 2014) .
Objective(s)/Endpoints:
Objectives Endpoints
Primary :  To assess whether 80 mg ixekizumab 
every 2 weeks ( Q2W )is superior to placebo at Week 
12 in the treatment of patients with moderate -to-
severe genital psoriasis as measured by static 
Physician Global Assessment (sPGA) of Genitalia 
(0,1)The proportion of patients achieving sPGA of Genitalia 
(0,1) at Week 12
I1F-MC-RHBQ Clinical Protocol Page 10
LY2439821Objectives Endpoints
Major Secondary :  To assess whether 80 mg 
ixekizumab Q2W is superior to placebo at Week 12 
in the treatment of patients with moderate -to-severe 
genital psoriasis as measured by change in itch, 
utilizing a modified genital psoriasis itch Numeric 
Rating Scale (NRS) item within the Genital Psoriasis 
Symptom Scale (GPSS)Mean change from baseline in the genital psoriasis 
itch NRS item within the GPSS at Week 12
Summary of Study Design:   
Study I1F -MC -RHBQ is a Phase 3, multic enter, randomized, double -blind, placebo -controlled, parallel -group, 
outpatient study examining the efficacy and safety of ixekizumab 80 mgQ2W dosing as compared to placebo for 12 
weeks , followed by a 40-week Open -Label Treatment Period with 80mgevery 4 week s(Q4W) dosing (with an 
option to step -up to 80 mg Q2W dosing) in patients with moderate -to-severe genital psoriasis .
Treatment Arms and Duration:   
There are 2 treatment groups in the Blinded Treatment Period, and patients will be randomized at Week 0 to 1of the 
groups. The 2 groups are :  ixekizumab 80 mg Q2W subcutaneous (SC) dosing and placebo Q2W SC dosing.  There 
is 1 treatment group in the Open -Label Treatment Period :  ixekizumab 80 mg SC Q4W dosing with an option to 
step-up to Q2W dosing starting at Week 24 through Week 4 0. The study duration will be up to 1 year for 
ixekizumab administration, and up to 1 year and 4 months for study participation over 4periods (Screening Period :  
7 to 30 days; Blinded Treatment Period :  12 weeks; Open -Label Treatment Period :  40 weeks; P ost-Treatment 
Follow -Up:  at least 12 weeks after the date of the patient’s early terminatio n visit [ETV] or last regularly scheduled 
visit).
Number of Patients :  
146randomized
Statistical Analysis:
For the Blinded Treatment Period, analyses of efficacy and health outcomes will be conducted on the intent -to-treat
(ITT) population, and safety analyses will be conducted on the safety population.
The primary analysis method for treatment comparisons of categorical efficacy and health outcome variables will b e
a logistic regression analysis with treatment and body surface area ( BSA )category as factors, using the 
nonresponder imputation (NRI) method.
The primary analyses for the continuous efficacy and health outcome variables will be performed using
mixed-ef fects model for repeated measures (MMRM) analysis .The model will include treatment, baseline BSA 
category, baseline value, visit, treatment -by-visit interaction, and baseline -by-visit interaction as fixed factors.  
A sequential multiple testing procedur e for the primary and the major secondary endpoint will be implemented to
control the family -wise ty pe I erro r rate at a 2 -sided α level of 0.05.
I1F-MC-RHBQ Clinical Protocol Page 11
LY2439821Fisher’s exact test will be used for all adverse event s(AE), b aseline, discontinuation, and other categorical safety
data. Continuous vital sign and laboratory values will be analyzed by an analysis of covariance (ANCOVA) with
treatment and baseline value in the model.
Consistency of results among the 2 subp opulations determined by baseline BSA category (<10% versus ≥10% 
baseline BSA involvement) will be assessed by performing additional subgroup analyses on the primary endpoint .
Thebaseline BSA category by treatment interaction will be tested at the signif icance level of 0.10. Treatment group 
differences will be evaluated within each baseline BSA categor y using Fisher’s exact test, regardless of whether the 
interaction is statistically significant.
I1F-MC-RHBQ Clinical Protocol Page 12
LY24398212.Introduction
2.1. Background
Chronic plaque p soriasis is a commo n, lifelo ng, and life -shortening chronic inflammatory  skin 
disease with an estimated prevalence in populat ions of approximately  3% which manifest sas 
prototy pic red, thi ck, and scaly plaques (Greaves and Weinstein 1995) .  Psori asishas b een 
shown to have a significant impact on t he overall health of pat ientswith considerable effects on 
social functioning and qualit y of life.
Approximately  29% to 63% of pati ents wi th chronic plaque psoriasis are impacted by psoria tic 
lesions in the geni tal area at som e point during the course of the disease (Fouéré et al. 2005; 
Meeuwis et al. 2010, 2011a; Ry an et al . 2015).  Due to mo istureand macera tion, genital psoriasis
cansometimeslack thecharacteris tic scale present at other body si tes (Buechner 2002; Weichert 
2004).  Both penile and vulvar psoria t
iclesions generally  appear as symmetri cal, bright red thin
plaques with a wel l-defined edge (Buechner 2002; Welsh et al. 2003; ISSV D 2014 [WWW ] ;
Meeuwi s et al. 201 5). Painful fissures and erosions can alsobea problematicclinical feature of
genital psoriasis (Barchin o
-Ortiz et al . 2012; Guglielmett i et al . 2012; Meeuwi s et al. 2015), and
severe pruri tusmay lead toscratchin gwithsignificant excor iations andlichenifica tion ( Weichert
2004; Guglielmett i et al. 2012) .
When co mpared to psoriasis pat ients without geni tal involvement, qualit y of life was found to be 
significant ly worse in pat ients with genital lesio ns (Meeuwis et al. 2011b , Ryan et al . 2015 ).  
Overall DermatologyLife Quali ty Index ( DLQ I)score, alldomainscores, andDLQI Question 9
(skin caused sexual difficul ties)were significan tlywors eforthosepsoriasispatients with current 
genital involvement compared to thosewithoutgenital lesio ns.  Itch and sexual impairment have 
been reported as key  bothersom e issues for patients with genital psoriasis (Meeuwis et al. 2015; 
Ryan et al . 2015).
Despite the significant impact on qualit y of life and sexual healt h, genital psoriasis is often not
discussed by pat ients (AAD Work Group et al. 2011; Meeuwis et al. 2012; Andreassi and 
Bilenchi 2014) ,and health care professio nals do not routinely  questi on or examine patients for 
its presence in clinical pract ice (Farber and Nall 1992; AAD Work Group et al. 2011).  While 
patients wi th geni tal psori asis often do not discuss their symptoms with healt h care providers, 
many patients report actively treating the irgenital lesions(Meeuwis et al. 2012).  Therefore, this 
may indicate a risk of self -treatm ent inthe genital area using medicat ionsthat were originally 
prescribed for treatment of other body locat ions.  Inappropriate self -treatm ent has the potential to 
resul t in less than optimal or over -treatm ent (f or exam ple, wi th potent corti costeroi ds) and 
significant adverse react ions.  Although genital psoriasis appears to be pathophysio logically  
ident ical to plaque psoriasis in other skin regions, the skin in this area is highly sensit ive and at 
increased risk of adverse reactions to topical treatments (CDA 20 09 [WWW]; Meeuwis et al. 
2011a; Guglielmetti et al. 2012).  Moreover , current lyavailable topi cal agents m ay not offer an
optimal or even appropriate level o f clinical improvement or tolerabilit y, especially for patients 
with moderate -to-severe genital pso riasis.  Weake rpotency corticostero ids often have limited 
efficacy  for use in m aintenance treatm ent (Welsh et al. 2003), and the use of higher potency
I1F-MC-RHBQ Clinical Protocol Page 13
LY2439821corticostero ids is limited due to the development of sk inatrophy andstriae (Linde nand
Weinstein 1999) . Irritat ion i s commonlyreporte d with vitamin D analogs (Scott et al. 2001;
Mason et al. 2013), and they may not be tol erated in the genital region ( CDA 2009 [WWW ]). 
Topicalcalcineurin inhibitors such as pimecrolimus and tacrolimus may improve genital 
psori asis but can cause irritancy  or a burning sensa tion, are not helpful in many patients (Menter
etal.2009; Meeuw is et al. 2011[a]) , and are not indicated for the treatm entofpsoriasi s. Beyond
suchtopical therapi es, there is rather limited evidence for viable therapeut icoptions to 
adequately  manage genital psoriasis. Forinstance,psorale nandultravioletA (PUV A)and 
narrowband ultraviolet B ( UVB )arenotadvised foruseinthegenital regiondue to potenti al 
carcinogenic adverse effects (Stern et al. 1990; Stern et al. 1994; Stern et al. 2002).
Current ly, there are limited data fro m clinical trials , parti cularly well -controlled therapeut ic 
intervent ional studies, which measure the efficacy of treatm ents f or geni tal psori asis.  To date, 
the only published treatment studies of genital psoriasis include open -label studi es of topical 
treatm ents (Jem ec and Baadsgaard 1993; Rallis et al. 2005; Mart ín Ezquerra et al. 2006; 
Bissonnette et al. 2008), a recent open -label study  of a stepwise treatment algorithm (Meeuwis et 
al. 2015), and scattered case reports.  
2.2. Study Rationale
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal
antibody  designed and engineered to select ively inhibit interleukin -17A (IL-17A) .  It binds with 
high affinit y (<3pM) and specificit y to IL -17A, a proinflammatory  cytokine. Neutralizat ion of 
IL-17A by ixekizumab has been shown to reduce excess kerat inocyte proliferat ion and act ivation
(Krueger et al. 2012). Ixekizumab does not bind to ligands IL -17B, IL -17C, IL- 17D, IL -17E, or
IL-17F .  
Phase 3 clinical trials of ixekizumab therapy were com pleted in pati ents wi th moderate -to-severe 
plaque psori asis with percentage of body  surface area (BSA) ≥10% . Ixekizumab was highly 
efficacious in these trials as evidenced by over 80% of patients achieving at least a 75% 
reducti on in thei rPsori asis Area and Severit y Index (PASI) from baseline (PASI 75) and o ver 
one-third having complete resolut ion of psori atic plaques (PASI 100) by Week 12 using a dosing 
regimen of 80 mg every  2 weeks fo llowing a 160 -mg starting dose (Griffit hs et al . 2015).  In 
addition, patients with mo derat e-to- sever eplaque psoriasiswhoweretreated with ixekizumab in
thesestudi es repor tedsignificant improvements asearly as W eek 2 insexua ldifficul ties 
compared toplacebo asmeasured by Q uesti on 9 of the DLQI .  Thus, i t is likely  that ixekizumab 
is effective in the genital region in pat ients with a baseline BSA ≥10% and may lead to 
improvement in sexual funct ion in these patients .  The most significant unmet medical need is in
patients wi th BSA <10% who have mode rate-to-severe genital psoriasis and limited treatm ent 
options because of the limitat ionsof topical and phototherapy  treatm ents f or geni tal psori asis
described in Secti on 2.1.
Based on the Phase 3 psoriasis clinical trialoutco mes, ixekizuma btherapy  in patients with
moderate -to-severe genitalpsoriasiscould address an unmet patient need and a clinical research 
gapidentified by the dermato logycommun ityand the American Academy of Dermatology Psori asis 
I1F-MC-RHBQ Clinical Protocol Page 14
LY2439821Guidelines of Care Working Group (Ryan et al. 2014) .One subcutaneous ( SC)ixekizumab regimen 
will be explored:  a 160 -mg starting dose fo llowed by  80 mg every  2 weeks (Q2W) for 12 weeks, 
and then 80 m g every 4 weeks (Q4W) with the opportunit y to step up to Q2W (Secti on 6.1).  The 
efficacy  and safety  profile of this ixekizumab dosing regimen was established in previous 
Phase 3 clinical studies of patients with moderate -to-severe plaque psoriasis .
I1F-MC-RHBQ Clinical Protocol Page 15
LY24398213.Objectives and Endpoints
Table RHBQ .3.1shows the object ives and endpo ints ofthe study .
Table RHBQ .
3.1. Objectives and Endpoints
Objectives Endpoints
Primary Objective Primary Endpoint
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital psoriasis as 
measured by sPGA of Genitalia (0,1)The proportion of patients achieving sPGA of 
Genitalia (0,1) at Week 12
Major Secondary Objective Major Secondary Endpoint
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital psoriasis as 
measured by change in itch, utilizing a modified 
genital psoriasis itch N RSitem within the GPSSMean change from baseline in thegenital 
psoriasis itch NRS item within the GPSS at Week 
12
Other Secondary Objectives Other Secondary Endpoints
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital psoriasis as 
measured by change in impact of genital psoriasis 
on sexual activity, utilizing the GPSIS, Sexual 
Activity  Avoidance SubscaleThe proportion of patients with at least a 2 -point 
improvement from baseline to Week 12 in the 
GPSIS, Sexual Activity Avoidance Subscale
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital ps oriasis as 
measured by change in frequency of sexual activity 
due to genital psoriasis , utilizing the SFQ item 2The proportion of patients with at least a 2 -point 
improvement from baseline to Week 12 in the 
SFQ item 2
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital psoriasis as 
measured by change in mGPASI Mean change from baseline in mGPASI at 
Week 12
To assess whether 80 mg ixekizu mab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate -to-severe genital psoriasis as 
measured by overall sPGA (0,1)The proportion of patients achieving overall 
sPGA (0,1) at Week 12
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients with moderate to severe genital psoriasis as 
measured by the following health outcomes 
measures :
oPatGA -Genital The proportion of patients with at least a 
2-point improvement from baseline to 
Week 12in PatGA-Genital
I1F-MC-RHBQ Clinical Protocol Page 16
LY2439821Objectives Endpoints
oDLQI
Total score
Item 9
DLQI (0,1)and DLQI 0Mean change from baseline in DLQI total 
score and Item 9 score at Week 12
The p roportion sof patients achieving 
DLQI (0,1)orDLQI 0 , respectively
oSF-36 Mean change from baseline on the SF -36 
PCS and MCS at Week 12
oGPSS 
Total score
Individual items other than itchMean change from baseline toWeek 12 in
GPSS total score and 
individual items (other than itch )
Evaluate the incidence of anti -ixekizumab 
antibodies and its relationship to patient efficacy of 
ixekizumab at Week 12The p roportion of patients achieving sPGA of 
Genitalia (0,1) at Week 12by TE -ADA status and 
by NAb status
Time course of response to treatment as measured 
by sPGA of Genitalia (0,1)The proportion of patients who achieve sPGA of 
Genitalia (0,1) over time t hrough Week 52
Time course of response to treatment as measured 
by mGPASIMean change in mGPASI over time through
Week 52
Exploratory Objectives Exploratory Endpoints
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
genital psoriasis patients with baseline BSA ≥ 10%
as measu red by overall PASIMean change from baseline in overall PASI at 
Week 12
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in genital psoriasis 
patients with baseline BSA ≥10% as measured by 
overall PASI 75 /90/100The proportion of patients achieving overall 
PASI 75/90/100 atWeek 12 
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in patients with 
moderate -to-severe genital psoriasis as measured 
by:
osPGA of Genitalia (0)
ooverall sPGA (0)The proportion of patients achieving 
osPGA of Genitalia (0) at Week 12
ooverall sPGA (0) at Week 12
To explore whether there is any impact of 
Fitzpatrick Skin Type on improvement measured by 
sPGA of Genitalia (0,1) response at Week 12Association between Fitzpatrick Skin Type 
(reported at base line) and sPGA of Genitalia (0,1) 
response at Week 12
To assess whether 80 mg ixekizumab Q2W is 
superior to placebo at Week 12 in the treatment of 
patients w ith moderate to severe genital psoriasis as 
measured by :
oGPSIS, Impact of Sexual Activit y on 
Genital Psoriasis Symptoms Subs cale for 
patients who reported being sexually 
active at baseline (score of “0” on GPSIS 
Question 1)The proportion of patients with at least a 
2-point improvement from baseline to 
Week 12in theGPSIS, Impact of Sexual 
Activity  on Genital Psoriasis Symptoms
Subscale for patients who reported a score of 
“0” on GPSIS Question 1 at baseline.
oSFQ item 1 The proportion of patients at each level of
SFQ item 1
I1F-MC-RHBQ Clinical Protocol Page 17
LY2439821Objectives Endpoints
oCAPP Genital subindex Mean change from baseline in the total 
CAPP Genital subindex score
oTouch Avoidance NRS Mean change from baseline in the Touch 
Avoidance NRS
To explore the impact of ixekizumab versus 
placebo at Week 12 on the change in presence or 
absence of fissure, ulcer, and/or erosion in the 
genital area and itsassociation with measures of 
quality  of lifeThe p roportion of patients with presence or 
absence of genital fissure, ulcer ,and/or erosion
and the association of absence/presence with 
measures of quality of life (SF -36 MCS , DLQI , 
GPSIS Subscales , and SFQ items ) in the 
subgroup of patients with fissure, ulcer, and/or 
erosion
To explore the impact of ixekizumab versus 
placebo at Week 12 on the change in presence or 
absence of psoriasis in perianal /gluteal cleft area (as 
indicated by the investigator in the case report 
form) and its association with measures of quality 
of lifeThe p roportion of patients with presence or 
absence of perianal /gluteal cleft psoriasis and the 
association of absence/presence with measu res of 
quality  of life (SF -
36 MC S, DLQI , GPSIS 
Subscales, and SFQ items ) in the subgroup of 
patients with psoriasis located in perianal area 
To explore the impact of ixekizumab versus 
placebo at Week 12 on the change in presence or 
absence of psoriasis on the face and itsassociation 
with measures of quality of lifeThe p roportion of patients with presence or 
absence of fac ialpsoriasis and the association of 
absence/presence with measures of quality of life 
(SF-36 MCS, DLQI ,and SFQ items ) in the 
subgroup of patients with psoriasis located o
nthe
face
To explore long-term impact of ixekizumab on 
symptoms and quality of life through Week 52The c hange over time through Week 52 in DLQI, 
SF-36 MCS, GPSS items, GPSIS Subscales , and 
SFQ items
To assess the psychometric properties (including 
reliability, validity, and responsiveness) of the 
GPSS, GPSIS, SFQ ,and sPGA of GenitaliaTest-retest reliability, construct validity ,and 
responsiveness will be assessed by ICCs, Pearson 
correlatio n/Spearman rank -based correlation 
coefficient , and correlations of calculated changes 
in scores , respectively, or as deemed appropriate
To measure ixekizumab exposure and assess the 
relatio nship between exposure and efficacy, and 
exposure and immunogenicit ySerum trough concentrations of ixekizumab
Model parameters for the exposure -response 
relatio nship between ixekizumab serum trough 
concentrations and efficacy endpoints
Ixekizumab serum trough concentrations 
associated with ADA titer subgroups
To explore biomarkers that are predictive of 
response to ixekizumab treatment that may be 
contained in DNA, RNA, serum, or plasma samplesAssociation between biomarker and ixekizumab 
response
I1F-MC-RHBQ Clinical Protocol Page 18
LY2439821Abbreviations:  ADA =anti-drug antibodies; BSA =body surface area; CAPP =Comprehensive Assessment of the 
Psoriasis Patient ;DLQI =Dermatology Life Quality Index; DLQI (0,1) =DLQI total score of 0 and1;
DNA =deoxyribonucleic acid ;GPSIS =Genital Psoriasis Sexual Impact Scale; GPSS =Genital Psoriasis 
Symptom Scale; ICC =
intraclass correlation coefficients ;MCS =mental component summary ;
mGPASI =modified Genital PASI ; NAb =neutralizing anti -drug antibody ; NRS =Numeric Rating Scale; 
PASI =Psoriasis Area and Severity Index; PASI 75 /90/100 = 75/90/100 % improvement frombaseline in the 
PASI; PatGA-Genital =Patient ’sGlobal Assessment of Genital Psoriasis ;PCS =physical component summary ; 
Q2W =every 2 weeks; SF -36 = Short-Form (36) Health Survey ;SFQ =Sexual Frequency Questionnaire; 
RNA =ribonucleic acid ; sPGA of Genitalia =static Physician Global Assessment of Genitalia ; 
TE-ADA =treatment -emergent anti -drug antibody .
I1F-MC-RHBQ Clinical Protocol Page 19
LY24398214.Study  Design
4.1. Overview of Study Design
Study  I1F-MC-RHBQ (RHBQ) is a Phase 3, mult icenter, randomized, double -blind, 
placebo -controlled, parallel- group, outpati ent study  examining the efficacy  and safet y of
ixekizumab as co mpared to placebo in patients with moderate -to-severe genital psoriasis .  The 
study  consists of 4 peri ods:
Period 1: Screening Period (Visit 1 and Visi t 1A) will  assess patient eligibilit yand start 
e-diary data collect ion, occurri ng approximately  7 to 30 days pri or to Peri od 2 (baseline; 
Week 0; Visit 2).
Period 2: Blinded Treatment Period will occur fro m Week 0 (Visit 2) up to Week 12 
(Visit 7).  Patients will be rando mized to ixekizumab or placebo in a 1:1 ratio.  
Two inject ions of ixekizumab 80 mg SC (total dose of 160 mg) or 2 inject ions of placebo 
SC, respectively , will be given at Week 0 (Visit 2) .  From  Week 2through Week 10 
patients will  receive ixekizumab 80 mg Q2W SC or pl acebo Q2W SC(Section 6.1).
Period 3: Open -Label Treatment Period will occur fro m Week 12 (Visit 7) up to
Week 52 (Visit 12).  At Week 12 (Visit 7) 1 inject ion of ixekizumab 80 mg SC and 1 
inject ion of placebo SC (total dose of ixekizumab 80 m g)will be given to patients who 
were randomized to ixekizumab in Period 2
;and 2inject ions of ixekizumab 80 mg SC
(total  dose of ixekizumab 160 m g) will be given to pati ents who were randomized to 
placebo in Peri od 2.  During the rem ainder of Period 3, patients will receive ixekizumab 
80 m g Q4W dosing wi th an opti on to step -up to Q2W dosing starti ng at Week 24 through 
Week 40 (at Visit 9 [Week 24], Visit 10 [Week 28], or Visit 11 [Week 40] )(Section 6.1).  
This open -label period will allow evaluat ion oflong-term efficacy  and safet y of 
ixekizumab through 1 year(52 weeks).
Period 4: Post-Treatment Follow -Up(Visit 801 through Visit 803) is for safet y 
monitoring after treatm ent di scontinuat ion for any  patient receiving at l east 1 dose of 
investigat ional product.  Once patients complete study treatment or discont inue study  
treatm ent early, patients will comple te the Post -Treatment Follow -Up (Peri od 4). This 
period occurs from the last treatment period visit or
early terminat ion visit (ETV) up to a 
minimum o f 12 weeks fo llowing that visit.
Figure RHBQ. 4.1illustrates the study  design , and a ll treatment groups andadministration of the 
investigat ional product aredescribed in Section6.1. The study 
drug administrati on log (SDAL) 
is described in Section6.2.1 . 
All procedures to be conducted during the study, including timing of all procedures, are indicated 
in the Schedule of Act ivities(Appendix 2 ).  Sel ected study  procedures shoul d be perform ed pri or 
to administration of the invest igational product , as applicable.  Appendix 3 lists the specific 
laboratory  tests that will  be perform ed for thi s study .  Pati ents discont inuing fro m the study  who 
have received at least 1 dose of investigational product will cont inue to the ETV prior to 
proceeding to the Post- Treatment Follow -Up Peri od (Peri od 4).  For the management of patient 
I1F-MC-RHBQ Clinical Protocol Page 20
LY2439821safet y, all pat ients should be monitored through the Post -Treatment Follow -Up Peri od at l east as 
frequently as indicated on the Schedule of Act ivities(Appendix 2 ).
Excluded and restricted therapies are detailed in Secti on6.8.
Pharmacokinet ic (PK) sampling is detailed in Section8.5.
Secti on9.9outlines the informat ion regarding the interim analyses including the primary 
database lock at Week 12 .
Figure RHBQ. 4.1illustrates the study  design.
I1F-MC-RHBQ Clinical Protocol Page 21
LY2439821Abbreviations :  inj = injection; LV = date of last visit; LY = LY2439821 (ixekizumab) ; n = number of patients; pt = patient; PBO = 
placebo; Q2W = ever y 2 weeks; Q4W = every 4 weeks; SC = subcutaneous; V = visit; W= study week.
a  Patients who discontinue the study for any  reason and w ho have received at least 1 dose of investigational product will continue 
to Early Termination Visit before entering the Post -Treatment Follow -Up Period.
b  All patients who increase dosing from 80 mg Q4W to 80 mg Q2W will remain on Q2Wuntil completion of the study (W52 or 
early  discontinuation ) (Section 6.1).
Figure RHBQ. 4.
1. Illustration of study design for Clinical Protocol I1F-MC-RHBQ .

I1F-MC-RHBQ Clinical Protocol Page 22
LY24398214.2. End of Trial Definition
End of the trialis the date of the last visit or last scheduled pro cedure shown in the Schedule of 
Activities(Appendix 2 )for the l ast patient.
4.3. Scientific Rationale for Study Design
Study  RHBQ includes a blinded treatm entperiod (Period 2) and an open -labeltreatm entperiod 
(Peri od 3) to determine the efficacy and safet y of ixekizumab .  During the 12-week blinded 
treatm entperiod, ixekizumab Q2W is compared to placebo Q2W, while during the 40-week 
open -label treatment period, patients are treated with ixekizumab Q4W.   
These period durations 
were chosen based on Phase 3 pivotal clinical studies in moderate -to-severe plaque psoriasis.   
The 12- week blinded treatment period will allow for the assessment of the response of moderate -
to-severe genital psoriasis to treatment with ixekizumab while limit ingexposure to placebo 
treatm ent.
The efficacy of ixekizumab will be primarily assessed at Week 12, using the static Physician 
Global Assessment (sPGA )of Geni talia.  In addit ion, efficacy at Week 12 will be assessed using 
outcom e measures such as the modified Genital PASI (mGP ASI)as well as the e-diary  to assess 
symptoms and impact of genital psori asis using the Genital Psoriasis Symptom Scale ( GPSS ), 
Genital Psoriasi s Sexual  Impact Scal e (GPSIS ),and Sexual Frequency Quest ionnaire ( SFQ).
All patients will begin ixekizumab 80 mg Q4W at Week 12 to assess the efficacy and safet y of 
ixekizumab treatment over the total 52 -week peri od.  During the Open -Label Treat ment Period 
(Peri od 3), pati ents m ay ‘step -up’ in dosing frequency fro m ixekizumab 80 mg Q4W to Q2W in 
order to achieve or maintain a sufficient level of efficacy (Section 6.1).  
4.4. Justification for Dose 
The ixekizumab dosing regimen of ixekizumab 80 mg Q2W for 12 weeks (starting dose 160 mg) 
and ixekizumab 80 mg Q4W for 40 weeks was chosen based on results from the pivotal Phase 3 
studi es which provided safet y and efficacy  data f or Q2W/Q4W dosing and Q4W/Q4W dosing 
following an init ial dose of 160 mg.  These studies did not evaluate Q2W dosing beyo nd 
12weeks ;however , continuous Q2W dosing is being evaluated in an ongoing study,
I1F-MC-RHBP. 
As no treat ment to date has been demo nstrated to be effective and safe for the treatment of 
moderate -to-severe genital psori asisin a controlled trial , placebo will be included as the 
comparator .
Study  RHBQ is designed to assess the efficacy and safet y profile o f theQ2W regimen in the first 
12 weeks (Blinded Treatment Period, Period 2) in patients with genitalpsori asis.  In addi tion, the 
study  will collect l ong-term safet y data for patients taking Q4W in the Open -Label  Treatm ent 
Period (Peri od 3), as well  as for those init ially taking Q4W who increase dose frequency to Q2W 
of ixekizumab during the Open -Label Treatment Period (Period 3) if they do not achieve or 
maintain sat isfactory  disease control  (Secti on 6.1).  
I1F-MC-RHBQ Clinical Protocol Page 23
LY24398214.5. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of ixekizumab are to be found in the 
Invest igator’s Brochure (IB).  
I1F-MC-RHBQ Clinical Protocol Page 24
LY24398215.Study  Population
The study  popul ationwill include patients with moderate -to-severe genital psoriasis who have 
given written informed consent approved by Eli Lilly  and Com pany (Lilly ), or i ts designee, and 
the ethi cal review board (ERB)/inst itutional review board (IRB) governing the site.
Study  investigator(s) will review patient records and screening test results fro m Visit 1, Vi sit 1A 
(as applicable for purified protein derivat ive[PPD]read), and Visit 2 to determine if the patient 
meets all inclusio n and exclusio n criteria to qualify for participat ion in the study as noted in 
Secti on 5.1and Sect ion 5.2, respectively .  All screening act ivities must be com pleted and 
reviewed before the patient is rando mized .  Individuals who do not meet study entry  criteria 
(screen failure) may be rescreened as described in Secti on 5.3.
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study .
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
5.1. Inclusion Criteria
Patients areeligible to be included in the study  only  if they  meet all  of the f ollowing criteria prior 
to randomizat ion as indicated below :
Type of Patient andDisease Characteristics
[1] Present wi th chronic plaque psoriasis based on a dia gnosis of chronic plaque 
psori asisfor at least 6 m onths before baseline (Week 0; Visit 2), as 
determined by the invest igator
[2] Are candidates for phototherapy  and/or sy stemic therapy
[3] Have an overall sPGA ≥3 at screening (Visit 1) and at baseline (Week 0, 
Visit 2)
[4] Have sPGA o f Genitalia ≥3 at screening (Visit 1) and at baseline (Week 0, 
Visit 2)
[5] Have BSA invo lvement of ≥1% at screening (Visit1) and at baseline (Week 0, 
Visit 2)
(Note:  Approximately 60% of  patients will  be requi red to have BSA 
involvement ≥ 10% and approximately  40% of  patients will  be allowed to 
have BSA invo lvement of 1 to <10%.  Enrollment will be closely mo nitored, 
and enrollment in this lower BSA subpopul ation will  be stopped if a 
maximum of 40% is reached. )
[6] Have confi rmation of plaque psori asis in a nongenital area at at screening 
(Visit1) and baseline (Week 0, Vi sit 2)
I1F-MC-RHBQ Clinical Protocol Page 25
LY2439821[7] Have failed to respond to, or are intolerant of, at least 1 topical therapy
(corticosteroi ds, calcineurin inhibitors and/or vitamin D analogs) used for 
treatm ent of psor iasis affect ing the genital area
Patient Characteristics 
[8] Are male or female pat ients of 18 years or older
[9] Must agree to use reliable method of birth control:
If a male patient, agree to use a reliable method of birth control during the
study  and f or at l east 12 weeks following the last dose of invest igational 
produ c
t.  Examples ofreliable m ethods include abstinence, vasectomy ,and 
male condo m with spermicide.
OR
If a female pat ient of childbearing potential, must test negative for pregnancy 
and agree to use a reliable method of birth control during the study and for at 
least 12 weeks fo llowing the last dose of invest igatio nal product .  Methods of 
contraception considered acceptable include abstinence, oral contraceptives, 
contraceptive patch, intrauterine device, vaginal ring, diaphragm wit h 
contraceptive gel, or condom with contraceptive gel .
OR
For nonchildbearing potential female patients, patients must be:   
Women who have had surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation)
OR
Women who are ≥60 y ears of age
OR
Women who are ≥40 and <60 years of age who have had a cessation of 
menses for ≥12 months and a fo llicle -stimulat ing hormone (FSH) test 
confirming nonchildbearing potential ( ≥40 mIU/mL)
Informed Consent
[10] Are able and h ave given wri tten informed consent approved by  Lilly, or i ts 
designee, and the IRB/ ERB governing the site
5.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teriaprior to 
rando mizat ion as indicated below :
Medical Conditions
I1F-MC-RHBQ Clinical Protocol Page 26
LY2439821[11] Have predo minant pattern of pustular, erythrodermic, and/or guttate forms o f 
psori asis
[12] Have pustul es or vesicles in the genital area
[13] Have a history  of drug -induced psori asis
Prior/Concomitant Therapy
[14] Have received syste mic nonbio logic psori asistherapy  or phototherapy  within 
4 weeks of baseline (Week 0, Visit 2), or have had topical psoriasis treatm ent 
within 2 weeks of baseline (Week 0, Visit 2) as specified in Table RHBQ. 6.2
Except ions(see Table RHBQ. 6.2):
mild corticosteroi ds will  be permi tted f or use limit ed to the face and/or 
axilla
[15] Cannot avoid excessive sun exposure or use of tanning booths for at least 
4weeks prior to baseline (Week 0, Vi sit 2) and during the study , per 
investigator assessment
[16] Concurrent or recent use of any  biologic agent wi thin the fo llowing periods 
prior to baseline (Week 0, Visit 2): etanercept <28 day s; infliximab or 
adalimumab <60 days; golimumab <90 days; uste kinumab <8 months; 
rituximab <12 months; or any  other bi ologic agent <5 half -lives
[17] Have ever received natalizumab or other agents that target alpha -4 integrin
[18] Haveever received treatment with IL-17 antagonists such as ixekizumab, 
secukinumab ,or brodal umab
Vaccinations
[19] Had a live vaccinat ion within 12 weeks prior to baseline (Week 0, Visit 2), 
intend to have a live vaccinat ion during the course of the study  or wi thin 
12weeks of com pleting treatment in this study, or have participated in a 
vaccine clinical study  within 12 weeks pri or to baseline. Invest igators should 
review the vaccinat ion status of their pat ients and follow the local guidelines 
for adul t vaccinat ion with nonlive vaccines intended to prevent infect ious 
disease pri or to therapy .
(Note :  
Killed/inact ive or subunit vaccines are expected to be safe; however, 
their efficacy with conco mitant ixekizumab treatment is unknown.)
[20] Had a vaccinat ion with Bacillus Calmette -Guérin (BCG) within 12 mo nths 
prior to baseline (Week 0, Visit 2) or intend to have vaccinat ion with BCG 
during the course of the study  or wi thin 12 m onths of co mpleting treatment in 
this study
Medical Status and Medical History
I1F-MC-RHBQ Clinical Protocol Page 27
LY2439821[21] Have a known allergy or hy persensi tivity to any  biologic therapy  that woul d, 
in the opinio n of the invest igator, pose an unacceptable risk to the patient if 
participat ing in this study
[22] Have current or a history  of lymphoproliferat ive disease or signs or symptoms 
of lymphoproliferat ive disease wi thin 5 y ears pri or to baseline (Week 0; Visit 
2); or have active or history  of malignant di sease wi thin 5 years prior to 
baseline (Week 0; Visit 2)  
(Note :  Patients with history of malignancy wit h no evidence of recurrence or 
active disease w ithin the 5 years prior to baseline may participate in the 
study .)
[23] Had any major surgery  within 8 weeks prior to baseline (Week 0, Visit 2) or 
will require such during the study  that, in the opinion of the invest igator in 
consultation wit h Lilly or its des ignee, woul d pose an unacceptable risk to the 
patient
[24] Presence of significant uncontrolled respiratory , hepati c, renal, gastrointestinal
(including Crohn’s disease or ulcerative colit is), endocrine, hematologic
(including a history  of bleeding disorder), neurol ogic,or neuropsychiatric 
disorders that would , in the opinio n of the investigator, pose an unacceptable 
risk to the pati ent if part icipating in the study or of interfering with the 
interpretati on of  data
[25] Presence of significant uncontrolled cerebroca rdiovascular (for example, 
myocardial  infarct ion [MI], unstable angina, unstable arterial hypertensio n, 
moderate to severe [New York Heart Association (NYHA) class III/IV] heart 
failure, or cerebrovascular accident [CVA]) that woul d, in the opinio n of the 
investigator, pose an unacceptable risk to the patient if participat ing in the 
study  or of  interfering with the interpretation of data
[26] Have electrocardiogram (ECG) abnormalit ies that are considered clinically 
significant and woul d pose an unacceptable risk to the pati ent if part icipating 
in the study , in the opinio n of the invest igator
[27] Have uncontrolled arterial hypertension characterized by a systolic blood 
pressure (BP) >160 mm Hg or diastolic BP >100 mm Hg at screening 
(Visit1) or at baseline rando mizat ion (Week 0, Visit 2)
(Note :  If an init ial BP reading exceeds this limit, the BP may be repeated 
once after the patient has rested sitting for ≥10 minutes.  If the repeat value is 
less than the criterion limits, the second value may be accepted.)
[28] Have had fluid overload, MI, or new onset ischemic heart disease (for 
example, unstable angina), uncompensated heart failure, or in the opinion o f 
the invest igator other serious cardiac disease within 12 weeks prior to baseline 
(Week 0; Visit 2)
I1F-MC-RHBQ Clinical Protocol Page 28
LY2439821[29] Recent h istory  of a suicide attem pt (≤30 days) , have a score of 3 on Item 12 
(Thoughts of Death or Suicide) of the Quick Inventory  of Depressive 
Symptom atology–Self  Report (16 i tems) (QIDS -SR16) at screening (Visit 1) 
or baseline (Week 0; Visit 2), or are clinically  judged by the invest igator to be 
at risk for suicide
[30] Have evidence or suspicio n of act ive or latent tubercul osis ( TB)(refer to 
Secti on 8.4.5 for details on determining full TB exclusion criteria)
[31] Are posi tive for hum an immunodeficiency virus serology  (HIV; posit ive for 
human immunodeficiency virus antibody  [HIVAb])
[32] Have evidence of or test positive for hepatit is B virus (HBV) by testing
:  1)
positive for hepat itis B surface ant igen (HBsAg+) OR 2) posit ive for 
anti
-hepat itis B core antibody ( HBcAb +) and areHBV DNA posit ive
(Note: Patients who are HBcAb+ and HBV DNA negat ive may be enro lled in 
the study . Patients who meet these criteria at scr eening will be ident ified by 
the central  laboratory  and m onitored during the study  as detailed in
Secti on8.4.8.2 .)
[33] Have evidence of or test positive for hepatit is C virus (HCV).  A posit ive test 
for HCV i s defined as :  1) posit ive for hepatit is C ant ibody  (anti-HCVAb) and 
2) posit ive via a confirmatory  test f or HCV (for example, HCV polymerase 
chain react ion).
[34] Have a body  temperature ≥38°C (10 0.5°F) at baseline (Week 0; Visit 2); these 
patients m ay be rescreened (1 time) ≥4 weeks after documented resolution of 
elevated tem perature.  Body  temperature will be determined via t ympanic or 
oral methods .
Infections 
[35] Had a seri ous infecti on (f or example, pneumo nia, cellulit is), have been 
hospi talized, or have received intravenous (IV) antibiot ics for an infect ion 
within 12 weeks pri or to baseline (Week 0, Visit 2); or had a serious bone or 
joint infect ion within 24 weeks pri or to baseline; or have ever had an infect ion 
of an artificial jo int; or are immunocompro mised to an extent such that 
participat ion in the study would pose an unacceptable risk to the patient
[36] Have or had an infect ion typical o f an immunocompromised host and/or that 
occurs with i ncreased incidence in an immunocompromised host (including, 
but not limited to, Pneumocy stis jirovecii pneumo nia, histoplasmosis, or 
coccidio idomycosis) or have a known immunodeficiency
[37] Have or had a herpes zoster or any other clinically apparent varicella -zoster 
virus infect ion within 12 weeks of baseline (Week 0, Visit 2)
I1F-MC-RHBQ Clinical Protocol Page 29
LY2439821[38] Have any other active or recent infect ion within 4 weeks of baseline (Week 0, 
Visit 2) that, in the opini on of the invest igator, would pose an unacceptable 
risk to the pati ent if part icipating in the study; these patients may be 
rescreened (1 time) ≥4 weeks after documented resolut ion of symptoms
[39] Have , or currently receiving treatment for, active candidiasis or tinea in the 
genital area.  Patients with act ive candidiasis or tinea in the g enital area may 
be treated and rescreened (1 time) ≥4 weeks after documented resolut ion of 
symptoms .
(Note: Invest igator may clinically assess for active infection as needed using 
potassi um hydroxide [KOH ]preparati on tests or other methodology per local 
procedures .)
Prior/Concurrent Clinical Trial Experience
[40] Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[41] Have previously co mpleted or withdrawn fro m this study  orparticipated in 
any other study  with ixekizumab, or have participated in any study  
investigat ing other IL -17 antagonists 
[42] Are current ly enrolled in, have participated, or discontinued fro m a clinical 
trial involving an invest igational product or nonapproved use of a drug or 
device wit hin the last 30 days or a period of at least 5 half- lives of the last 
administration of the drug, whichever is longer, or concurrent ly enro lled in 
any other ty pe of medica l research j udged not to be sci entifically or medically 
compatible with this stud y(eg, observat ional study requiring blood draws, 
biopsies , and/or other intervent ional monitoring procedures)
Diagnostics Assessments
Laboratory  tests shoul d not be repeated unless there is a technical error or clinical 
reasons to believe a result may be erroneous (except for e xclusio n criteria 
[46]).
[43] At screening, have a neutrophil count <1500 cells/μL (<1.50x10 3/µL or 
<1.50 GI/L)  
[44] At screening, have a lymphocy te count <800 cells/μL (<0.80x10 3/µL or 
<0.80 GI/L)  
[45] At screening, have a platelet count <100,000 cells/μL (<100x10 3/µL or 
<100 GI/L)  
[46] At screening, have aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 times the upper limit  of normal (ULN)
I1F-MC-RHBQ Clinical Protocol Page 30
LY2439821(Note:  The AST and ALT may be repeated once within a week if the init ial 
response exceeds this limit, and the repeat value may  be accepted if it meets 
this criterion.)
[47] At screening, have a total white blood cell (WBC) count <3000 cells/μL 
(<3.00x10 3/µL or <3. 00 GI/L) 
[48] At screening, have hemoglo bin <8.5 g/dL (85.0 g/L) for male patients and 
<8.0 g/dL (80 g/L) for female patients 
[49] Have other clinical laboratory  test resul ts at screening that are outside the 
norm al reference range for the populat ion and are consi dered clinically 
significant, per invest igator assessment 
Other Exclusions
[50] Have donated more than 1 unit (approximately  450 mL )of blood wi thin the 
last 4 weeks prior to screening (Visit 1) or intend to donate blood during the 
course of the study .  These patients may be rescreened (1 time) to allow the 
requi red 4 -week minimum time since donation of more than 1 unit of blood.
[51] Are women who are lactating or breast feeding
[52] Have any other condit ion that precludes the patient fro m following and 
completing the p rotocol , in the opinio n of the investigator
[53] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[54] AreLilly  empl oyees or its desi gnee or are emplo yees of third -party  
organi zations (TPOs) invo lved in the study
[55] Are unwilling or unable to comply  with the use of a data collect ion device to 
directly record data from the subject
5.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened in the fo llowing ci rcumstances: Patients who test posi tive forlatent TB at screening 
may be rescreened fo llowing appropri ate treatm ent as described in Section 8.4.5 ;patients who do 
not qualify at screening under exclusio n criteria [34], [ 38 ], or [ 39]may be rescreened once, 4 or 
more weeks after document ed resol ution of  symptom s.  Pati ents who do not qualify  at screeni ng 
under exclusio n criterion [50 ] may be rescreened once to allow the required 4- week minimum 
time since donat ion of more than 1 unit of blood.   When rescreening is performed, the individual
must si gn a new informed consent form ( ICF) and will be assigned a new ident ificat ion number.   
Addit ionally , all screening procedures m ust be conducted to ensure all eligibilit y criteria are m et.
5.4. Lifestyle and/or Dietary Requirements
See inclusio n criterion[9] in Section 5.1for birth control  requi rements .
I1F-MC-RHBQ Clinical Protocol Page 31
LY24398216.Treatment
6.1. Treatments Administered
The Blinded Treatment Period (Period 2) invo lves a com parison of ixekizumab 80 m g Q2W 
(starting dose of 160 mg) and placebo Q2W .All doses are administered via SCinject ion. 
Allpatient sassigned to ixekizumab 80 mg Q2W regimen will receive a starting dose of 160 mg 
ixekizumab as 2SCinject ions.  The pl acebo group will receive 2 SC inject ionsof placebo at this 
visit as well, to maintain the blind.
For training purposes, the starting dose of 160 mg (two 80- mg SC inject ions) will be 
administered at the clinic at Week 0 (Visit 2).  T he first injection will be ad ministered by  clinical 
staff,and the second injection will be administered by  the pat ient or the patient’s caregiver while 
under supervisio n of clinical staff.  Subsequent injections of invest igational product will be 
administered by  the pat ient or the pa tient’s caregiver unsupervised by  the clinical  staff, 
regardl ess of whether there is a study  visit scheduled except at Visit 7 (Week 12) . At Visit 7 
(Week 12) ,the 2 injections will be administered by the patient or the patient’s caregiver 
supervised by t he clinical staff to all ow for vital sign m onitoring (Section 8.4.2).  It is 
recommended that all subsequent inject ions be administered outside the trial site, preferably  at 
the patient’s ho me.
A dose of invest igational product will consist of 1 SC inject ion of ixekizumab or placebo.  
Possible inject ion sites include the abdo men (upper l eft, upper ri ght, l ower l eft, or l ower ri ght 
quadrant [with the umbilicus being the center]), left or right thigh, and left or right upper arm.  If 
the upper arm is ut ilized as the inject ion site, the inject ion must be administered by  a caregive r.  
The inject ion site should not be in a psoriatic lesio n.  On days when mult iple inject ions will be 
administered, the inject ion sites should be in different areas (note the abdo men has 4 possible 
inject ion areas).
At Week 12, d uring the Open -Label Treat mentPeriod (Period 3), all pat ients will be reassigned 
to ixekizumab 80 mg Q4W.  Patients originally assigned to placebo will receive a blinded
ixekizumab starting dose of 160 mg as 2 SC inject ions.  To m aintain blinding, p atients ori ginally 
assigned to ix ekizumab 80 m g Q2W will receive a blinded ixekizumab 80 -mg dose and a 
placebo dose at Week 12 .  Dosing may be increased in the Open -Label Treatm entPeriod
(Peri od3)to ixekizumab 80 mg Q2W, starting at Week 24 through Week 40 (at Visit 9 
[Week 24], Visit 10 [Week 28], or Visit 11 [Week 40]) , if the pat ient is eligible to receive 
additional invest igational product (that i s, if it is determined by the patient and the investigator 
that the patient needs addit ional ixekizumab in order to achieve or maintain sa tisfactory  disease 
control ).  All  patients who increase dosing to 80 mg Q2W will remain on this dose until 
completion of the treatm ent peri odor early discontinuat ion.  Table RHBQ .6.1shows the 
treatm ent regimens .  
If patients remain on ixekizumab 80 mg Q4W, their last dose will occur at 
Week 48.  If patients step up to ixekizumab 80 mg Q2W, their last dose will occur at Week 50.
Treatment received during the Blinded Treatment Period (Period 2) will remain blinded to 
investigators, study  site personnel , and pati ents until  all pati ents have co mpleted Week 52
I1F-MC-RHBQ Clinical Protocol Page 32
LY2439821(Visit 12) or have discont inued fro m the study  (moved into Post -Treatment Follow -Up 
[Period4]).
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational product to the patient/patient care giver
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing, collect ion, and 
administration
returning all unused medication to Lilly  or its designee at the end of the study
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem wit h the invest igational product so that the situation can be assessed.
Further instructions and special considerat ions forthe administration o f the invest igational 
product are provided in Secti ons 6.2.1 and 6.6.1.
I1F-MC-RHBQ Clinical Protocol Page 33
LY2439821Table RHBQ .6.1. Treatment Regimens
Randomized Treatment 
ArmDose
Week 0 (Day 1)Dose
Week 2 to Week 10 Dose
Week 12Dose
Week 16 to Week 50a
Blinded Dosing Open -Label Dosing
Ixekizumab
80 mg 2 ixekizumab 80 -mg 
injections1 ixekizumab 80 -mg 
injection Q2W 1 ixekizumab 80 -mg 
injection
1 placebo injection 1 ixekizumab 80 -mg injection 
Q4W with Q2W step -up as 
needed b
Placebo 2 placebo injections 1 placebo injection Q2W 2 ixekizumab 80 -mg 
injections 1 ixekizumab 80 -mg injection 
Q4W with Q2W step -up as 
needed b
Abbreviations:  Q2W = ever y 2 weeks; Q4W = every 4 weeks .
aIf patients remain on ixekizumab 80 mg Q4W, their last dose will occur at Week 48.  If patients step up to ixekizumab 80 mg Q 2W, their last dose will occur 
at Week 50 (Section 6.1).
bDosing may be increased to ixekizumab 80 mg Q2W starting at Week 24 through Week 40 (at Visit 9 [Week 24], Visit 10 [Week 28], or Visit 11 [Week 40]).  
Once a step -up from Q4W to Q2W occurs, the dose is maintained at Q2W for the remainder of the treatment period (Section 6.1).
I1F-MC-RHBQ Clinical Protocol Page 34
LY24398216.2. Method of Treatment Assignment
Patients who meet all criteria for enrollment will be randomized to blinded treatment at Visit 2
(Week 0) in a 1:1 ratio to ixekizumab 80 mg Q2W or placebo .  Assignment to treatment groups 
will be determined by a co mputer -generated random sequence using an interactive web -response 
system  (IWRS).  The IWRS will be used to assign double- blind investigat ional product to each 
patient.  Si te personnel will confirm that they  have l ocated the correct assigned invest igational 
product package by entering a confirmat ion number found on the package into the IWRS.
To achieve between -group com parabilit y for BSA ,the rando mizat ion will be stratified by 
BSA (1%to <10% versus ≥10%) .
6.2.1. Selection and Timing of Doses
Patients ar e randomized to dosing regimen sand will receive their assigned invest igational 
product as outlined in Sect ion 6.2and Secti on 6.1, respectively .  
Invest igational product should be administered at approximately the same t ime of day each time, 
as much as possible.  For inject ions that are missed and not administered on the scheduled day o f 
the week, the missed dose should be administered within 5days o f the originally  scheduled day .
Dates of subsequent study  visits shoul d not be m odified according to the delay  of the inject ion of 
the missed scheduled dose .
Throughout t heir participation in the study, randomized pat ients and/or site personnel will record
inform ation in a Study  Drug Administrati on Log, including the date, time, and anatomical
location of administration of investigational product (for treatment compliance) , syringe number,
who administered the invest igational product, and the reason if invest igational product was not
fully administered.
6.3. Blinding
This is a double -blind study .  To preserve the blinding of the study , a minimum  number of Lilly  
personnel will see the rando mizat ion table and treatment assignments before the study  is 
complete.
Emergency  unblinding for AEs may be performed through the IWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the patient’swell-being requires knowledge of the patient’s treatm ent 
assignment.  All actionsresul ting in an unbli nding event are recorded and reported by  the IWRS .
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient
must be discont inued fro m the study treatm ent.  All patients should continue to be followed for 
safet y (Period 4).  In cases where there are ethical reasons to have the patientremain on study
treatm ent, the invest igator must ob tain specific approval from a Lilly  clinical  research physician 
(CRP) for the patientto continue study treatm ent.  
In case of an emerge ncy, the invest igator has the sole responsibilit y for determining if unblinding 
of a patient’s treatment assignment is warranted.  Patient safet y must always be the first 
I1F-MC-RHBQ Clinical Protocol Page 35
LY2439821consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tact the Lilly CRP prior to unblinding 
a patient’s treatment assignment.  If a patient’s treatment assi gnment i s unblinded, Lilly  must be 
notified immediately by tel ephone, em ail, or fax .  Including this unblinding information in the 
SAE report is not sufficient for notificat ion purposes .
6.4. Packaging and Labelling
The invest igational products will be supplied by the sponsor or its designee in accordance wit h 
current Good Manufacturing Practices (cGMP).  
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.  All 
investigat ional products will be stored, inventoried, reconc iled, and destroy ed according to 
applicable regulat ions. 
Ixekizumab and placebo to match (excipients only) will be supplied as an injectable so lution in 
1-mL, single -dose, prefilled, disposable manual syringes wit h study  specific labels.  Each sy ringe 
of ixekizumab is designed to deliver ixekizumab 80 m g.  The sy ringes (and contents) containing 
either ixekizumab or placebo will  be visibly indist inguishable from each other.  Sy ringes will be 
supplied in cartons ;
each carton will contain the appropriate quan tity of syringes specific to the 
planned dispensing schedule of the invest igational product.
6.5. Preparation/Handling/Storage
Invest igational products will be supplied by Lilly or its representative, in accordance wit h 
cGMP ,and will be supplied with lot numbe rs, expiry  dates, and certificates of analysis, as 
applicable.
The invest igational product should be stored at 2°C to 8°C (36°F to 46°F) in its original carton to 
protect from light.  Invest igational product should not be frozen.  Sites will be required to
monitor tem perature of the on -site storage condit ions of the invest igational product.
6.6. Dose Modification
Dose adjust ments are not permitted for the Q2W dosing regimen during the Blinded Treatment 
Period (Peri od 2).  During the Open -Label Treatment Period (Peri od 3) ,patients will receive 
continuous Q4W dosing fro m Week 12 through Week 20.  Patients may step-up the Q4W dosing 
regimen to Q2W starti ng at Week 24 through Week 40 as outlined in Sect ion 6.1.  Once a 
step-up to Q2W occurs, the dose is maintained at Q2W for the remainder of the Open -Label  
Treatment Period (Period 3) .
6.6.1. Special Treatment Considerations 
Patients will  be screened for eligibilit y in the study as described in Sect ion 5.1andSecti on5.2
and will be informed of the study -specific restrict ions and requirements of the study.  Patients 
who are not willing to comply with the study  restricti ons and requi rements of the study  will not 
be eligible for enro llment.
I1F-MC-RHBQ Clinical Protocol Page 36
LY2439821Patients shoul d be instructed not to donate blood or blood products during participat ion in the 
study .  
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestations of these reacti ons m ay include, but are not limit ed to:
skin rash
pruri tus (i tching)
urticaria (hives)
angioedema (for example, swelling of the lips and/or tongue)
anaphylactic reaction
Sometimes, these reactions can be life -threatening.  Proteins may also cause redness, itching, 
swelling, or pain locally at the inject ion site.  Therefore, all pat ients should be closely mo nitored 
for signs or symptoms that could result from such reactions , educated on the signs or symptoms 
of these ty pes of  react ions, and instructed to contact the study site immediately if any of the 
symptoms are experienced fo llowing an inject ion.  If a patient experiences an acute 
allergic/hypersensit ivity react ion after an inject ion of investigational product, he or she should be 
managed appropriately and given instruction to receive relevant supportive care.  Addit ionally, 
for an event j udged by  the invest igator to be a potent ial systemic allergic/hypersensit ivity 
react ion, a blood sample should be drawn as soon as possible .These samples may be tested for 
anti-drug ant ibodies ( ADAs ), other l aboratory  tests needed to el ucidate the cause of the 
allergic/hypersensit ivity react ion, and/or ixekizumab serum concentration.   These results will not 
be provided to the invest igator for patient care decision sbut are intended to assist the sponsor in 
accurately characteri zingthe reacti on.
For pati ents who experience a potential allergic/hypersensit ivity react ion, consideration for any  
prem edicat ion for future inject ions will be agreed upon between the investigator and sponsor 
and/or its designee.  Examples o f potenti al allergi c/hypersensit ivity react ions that might merit 
prem edicat ion include mild -to-moderate skin rashes, mild -to-moderate generalized pruritus 
and/or urti caria, and mild -to-moderate inject ion-site reacti ons (for example, injection -site 
erythema, inject ion-site pruri tus).  Pati ents who develop clinically  significant sy stemic 
allergic/hypersensit ivity react ions following administration of invest igational product and who 
do not respond to symptomat ic medicat ion or who experience clinical sequelae (for example, 
hospi talizati on) sho uld be discontinued fro m study treatm ent and shoul d not receive further 
doses of invest igational product, with or without premedicat ion (see Section 7.1).  Medi cations 
considered appropriate for premedicat ion include but are not restricted to 
acetaminophen/paracetamo l up to 1000 m g and antihistamines (for example, oral 
diphenhydramine, 50 mg), given 30 to 60 minutes prior to investigational product in jection.  
Patients m ay self-premedicate at hom e prior to administration of invest igational product, as 
directed by  the invest igator.  All such premedicat ions will be recorded as concomitant therapy.  
Corti costeroi ds are not permitted as agents for premedic ation.
I1F-MC-RHBQ Clinical Protocol Page 37
LY24398216.7. Treatment Compliance
Every  attem pt will be m ade to sel ect pati ents who have the abilit y to understand and co mply with 
instructi ons.  To ensure high treatment compliance, t he invest igator is responsible for discussing 
methods with the patient before randomization .
Patient com pliance wi th the invest igational product (Section 9.4.4 )will be assessed at each study  
visit during the Blind edTreatment and Open- Label Treat ment Periods (Peri ods 2 and 3) by 
review of the SDAL (Secti on 6.2.1 ), return of empty  invest igational product packagi ng, and/or 
direct questi oning .  Deviat ion(s) fro m the prescribed dosage regimen should be documented.
If,in consultat ion with Lilly or i ts desi gnee ,the nonco mpliance is deemed to be significant or if 
further nonco mpliance occurs, the patient should be di scont inued fro m the study
(seeSecti on7.1.3 ).
6.8. Concomitant Therapy
All conco mitant m edicat ion taken during the study must be recorded on the Concomitant 
Medicat ion case report form ( eCRF ) at the study  visitsindicated in the Schedule of Activities 
(Appendix 2 ).  Treatm ent wi th concomi tantpsoriasis therapi es during the study  will be permitted 
only as outlined in the exclusion criteria (Sect ions5.2) and as described in the table below .  
Patients taking permitted medications should be on stable doses at the baseline visit (Week 0 ,
Visit 2) as specified in Secti on5.2.  Table RHBQ. 6.2summarizes conco mitant m edicat ion sthat 
are or are not permitted for use during the study and related comments and condi tions f or use .
I1F-MC-RHBQ Clinical Protocol Page 38
LY2439821Table RHBQ. 6.2. Concomitant Medication Permitted/ Not Permitted in the Study 
Drug Class Use During Study Comments/Conditions
SYSTEMIC THERAPIES
Biologic agent other than 
investigational product as part of 
this protocolNot permitted Minimum required time since last biologic agent dose 
prior to baseline (Week 0, Visit 2) :  
etanercept –at least 28 days
infliximab, adalimumab –at least 60 days
golimumab -at least 90 days
ustekinumab –at least 8 months
rituximab –at least 12 months
any other biologic agent –at least 5 half -lives
IL-17 antagonists, other than investigational product as 
part of this protocol :  
Must never have received, or participated in any 
study investigating, IL -17 antagonists
Examples include :  ixekizumab, secukinumab, 
brodalumab
Natalizumab , or other agents 
targeting α 4 integrinNot permitted Must have never received
Systemic nonbiologic psoriasis 
therapyNot permitted Must not have received within 4 weeks prior to
baseline (Week 0, Visit 2)
Examples include :oral PUVA light therapy, 
cyclosporine, corticosteroids, MTX, apremilast, 
tofacitinib, oral retinoids, mycophenolate mofetil, 
thioguanine, hydroxyurea, si rolimus, 
azathioprine, fumaric acid derivatives , 1, 25 
dihydroxy  vitamin D3 and analogs
PHOTOTHERAPY
Phototherapy Not permitted Must not have received within 4 weeks p rior to 
baseline (Week 0, Visit 2)
Examples include : either oral and topical PUVA 
light therapy, UVB, self -treatment with tanning 
beds or therapeutic sunbathing
I1F-MC-RHBQ Clinical Protocol Page 39
LY2439821Drug Class Use During Study Comments/Conditions
TOPICAL THERAPIES
Bath oilsand oatmeal bath 
preparationsPermitted with conditions Not to be used within 12 hours prior to a study 
visit
Shampoos NOT containing 
salicylic acid, corticosteroids, coal 
tar, o r vitamin D analogsPermitted with conditions Not to be used within 12 hours prior to a study 
visit
Shampoos and Scalp Treatments
containing salicylic acid, 
corticosteroids, coal tar , or vitamin 
D analogsNot permitted Must not be u sed within 2 weeks prior to baseline 
(Week 0, Visit 2).  
Topical moisturizers/emollients 
and other nonprescription topical 
products NOT containing urea, 
salicy lic acid, alpha -or beta -
hydroxy l acids, corticosteroids, or 
vitamin D analogsPermitted with conditions Not to be used within 12 hours prior to a study 
visit
Topical moisturizers/emollients 
and other nonprescription topical 
products containing urea, salicylic 
acid, alpha -or beta -hydroxy l acids, 
corticosteroids, or vitamin D 
analogsNot permitted Must not be used within 2 weeks prior to baseline 
(Week 0, Visit 2 ). 
Topical corticosteroids, more 
potent than mildNot permitted Must not be used within 2 weeks p rior to baseline 
(Week 0, Visit 2).
I1F-MC-RHBQ Clinical Protocol Page 40
LY2439821Drug Class Use During Study Comments/Conditions
Topical corticosteroids, low to 
mild potencyPermitted with conditions Must not be used within 2 weeks prior to baseline 
(Week 0, Visit 2).  
Study Periods 1 and 2:  Not permitted for use 
except toface and/or axilla .  If used for face 
and/o r axilla , may not be used within 
approximately 24 hours prior to study visits 
requiring sPGA and PASI measures 
Study Periods 3 and 4:  Permitted for use , as 
needed, after Week 12 assessments are complete 
but not for the genital area.  May not be used 
within approximately 24 hours prior to study 
visits requiring sPGA and PASI measures.
Examples include :  desonide , hydrocortisone
Other prescription topical 
productsNot permitted Must not be used within 2 weeks prior to baseline 
(Week 0, Visit 2) 
Examples include : calcineurin inhibitors, 
anthralin, vitamin D analogs ,andretinoids
VACCINES
Vaccine, Bacillus Calmette -
Guérin (BCG)Not permitted Must not have received within 12 months prior to 
baseline (Week 0, Visit 2)
Should not receive within 12 months of 
completed treatment in this study
Vaccines, live Not permitted Must not have received within 12 weeks prior to 
baseline (Week 0, Visit 2)  
Should not receiv e within 12 week s of completed 
treatment in this study
Vaccines, nonlive seasonal and/or 
emergencyPermitted with conditions Killed/inactive or subunit vaccines are expected 
to be safe; however, their efficacy with 
concomitant ixekizumab treatment is unknown
OTHER
NSAIDs, aspirin, or 
acetaminophen/paracetamolPermitted Allowed as needed
Abbreviations:  IL = interleukin; MTX = methotrexate; NSAID = nonsteroidal anti -inflammatory drug; PASI = Psoriasis Area and Severity Index; 
PUVA =psoralen and ultraviolet A; sPGA = static Phys ician Global Assessment; UVB = ultraviolet B.
I1F-MC-RHBQ Clinical Protocol Page 41
LY2439821Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatm ent of an ongoing medical problem.  If the need for concomitant medication arises for an 
AE or for appropriat e medical  management (including the limited use of therapeutic agents 
which, if used under treatment regimens other than for treating an AE or for appropriate medical 
management, might be considered psori asistherapies), the invest igator should base decisi ons on 
the pati ent and clinical factors .  Any addit ional medication, whether prescription or over -
the-counter, used at baseline (Week 0 , Visit 2) and/or during the course of the study  must be 
docum ented wi th the start and stop dates on the Conco mitant Medi cations eCRF.
Patients will  maintain thei r usual medicat ion regimen for other concomitant diseases throughout 
the study  unless those m edications are specifically  excluded in the protocol .  Pati ents taking 
concomitant medicat ions should be on stable doses at the time of baseline (Week 0 ,Visit 2) and 
shoul d remain at a stabl e dose throughout the study , unless changes need to be made for an AE 
or for appropriate medical management.  Other medicat ions may be allowed if approved by  the 
sponsor or its designee.
6.9. Treatment after Study Completion
6.9.1. Continued Access
Invest igational product will not be made available to patients after conclusio n of the study .
I1F-MC-RHBQ Clinical Protocol Page 42
LY24398217.Discontinuation Criteria
7.1. Discontinuation from Study Treatment
The reason for and date of discont inuat ion from study treatment (invest igational product) and
reason for and date of discont inuat ion from study participat ion will be collected for all
randomized patients.
For any  patient discontinuing fro m study  treatm ent, the invest igational product will be withheld,
and the patient will co mplete the ETV and the Post -Treatment Follow -Up Peri od (Peri od 4), as
shown in the Schedule of Act ivities (Appendix 2 ).
Missing data may co mpro mise the integrit y of the study .Com plete informat ion from each 
patient is cri tical to achi eving the fullest understand ing of the potential benefit s and risks o f 
ixekizumab. All efforts should be made to keep patients in the study , toattend scheduled visits 
and procedures, and to take invest igational product as medically appropri ate.
Patients who m eet any  of the cri teria described in Section 7.1.1 will be discont inued fro m the 
study  treatm ent.
7.1.1. Permanent Discontinuation from Study Treatment
Patients will  permanent ly discont inue from study  treatm ent in the fo llowing si tuations:
[1] Discontinuati on of  the invest igational product for abnormal liver tests should 
be considered by  the invest igator when a patientmeets 1 of the fo llowing 
cond itions after consultation wit h the Lilly designated medical mo nitor:
ALT or AST >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
prothrombin t ime >1.5X ULN
ALT or AST >3X ULN with the appearance of fatigue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%
of total  leukocy tes)
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5 ULN with the appearance of fatigue , nausea, vomit ing, right 
quadrant pain or tendernes s, fever, rash, and/or eosinophilia (>5%)
In addit ion, patients will be discont inued fro m the investigat ional product in the fo llowing 
circumstances:
[2] Laboratory  resul ts:
Neutrophil (segmented) counts (see safet y monitoring for neutropeni a in 
Secti on8.4.8.1 );
o<500 cells/ L (<0.50x 103/µL or <0.50 GI/L)
I1F-MC-RHBQ Clinical Protocol Page 43
LY2439821o≥500 and <1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor 
≥0.50 GI/L and < 1.00 GI/L) (based on 2 test results; the second test 
perform ed wi thin 1week fro m knowl edge of  the ini tial resul t) 
o≥1000 and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L 
and <1.50 GI/L) (based on 3 test results as specified in Sect ion8.4.8.1 )
-AND -a concurrent infect ion
Total  WBC count <2000 cells/ L (<2.00x103/ µL or <2.00 GI/L)
Lymphocy te count <500 cells/μL (<0.50x10 3/µL or < 0.50 GI/L)
Platelet coun t <50,000 cells/ μL (<50x10 3/µL or <50 GI/L )
[3] Changes in BP (systolic BP at ≥160 mm Hg plus ≥20 mm Hg increase fro m 
baseline [Week 0; Visit 2]; and/or diastolic BP at ≥100 mm Hg plus 
≥10mmHg increase from  baseline) that do not respo nd fo llowing 
intervent ion (Section 8.4.8.3 )
[4] The patient experiences a severe AE, a nSAE, or a clinically significant 
change in a laboratory  value occurs that, in the opinio n of the investigator, 
merits the discontinuation of the invest igational product and appropriate 
measures being taken.  In this case, Lilly or its designee is to be no tified 
immediately .  Refer to Adverse Events ,Section 8.2.
[5] Clinically significant sy stemic hypersensit ivity reacti on following SC 
administration of invest igational product that does not respond to 
symptom atic medicat ion or resul ts in clinical sequelae
[6] The patient beco mes pregnant.  Patients will undergo urine pregnancy self -testing at 
home on a monthly basis during periods between scheduled visit s until Week 52.   
During these intervisit periods, the site must call the patient each month to obtain her 
pregnancy test results.   Additional urine pregnancy testing can be performed at the 
investigator’s discret ion. Patients that are determined to be pregna nt will be 
discontinued fro m treatment and will no longer be administered invest igational 
product.
[7] The patient develops a malignancy.
(Note :  Patients may be allowed to con tinue if they  devel op no m ore than 
2nonmelano ma skin cancers during the study .)  
[8] Any pat ient who has a change in disease phenoty pe at any  time (for ex ample, 
a change to pustular psori asis)
[9] If the patient requires long -term treatm ent wi th a therapeut ic regimen that has 
been demo nstrated to be effective for the treatment of psori asis  
[10] Enrollment in any other clinical trial invo lving an investigational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
I1F-MC-RHBQ Clinical Protocol Page 44
LY2439821[11] The patient scores a 3 for Item 12 (Thoughts of Death or Suicide) on the 
QIDS -SR16 at any  time in the study .The patient should be evaluated on -site 
for risk of suicide and/or referred to a mental healt h provi der for assessment.
[12] The invest igator or attending physician decides that the patient should be 
withdrawn from study treatm ent.
[13] The patient requests to be withdrawn fro m study treatm ent.
[14] The invest igator or Lilly stops the patient’s participation in the study.
[15] The patient beco mes HBV DNA posit ive.  The patient should be referred to a 
specialist physician.  Discussio n of the timing of discontinuation fro m the 
study  and study  treatm ent is provi ded in Sect ion8.4.8.2 .
If a patient is nonco mpliant with study  procedures and/or invest igational product administration, 
the invest igator should assess the patient to determine the reason for noncompliance and educat e 
and/or manage the patient as appropriate to improve compliance (Secti on 6.7).
Patients who discont inue the invest igational product early will have an ETV and end-of-therapy  
procedures performed as shown in the Schedule of Act ivities (Appendix 2 )and will cont inue into 
the Post Treatment Fo llow-up Peri od.
7.1.2. Discontinuation of Inadvertently Enrolled Patients
The cri teria for enrollment m ust be fo llowed explici tly.  If the sponsor or invest igator ident ify a 
patient who di d not m eet enrollment criteria and was inadvertent ly enrolled, a di scussio nmust 
occur between the sponsor CRP and the invest igator to determine if the patient may cont inue in 
the study treatm ent.  If both agree it is medically  appropri ate to con tinue, the investigator must 
obtain docum ented approval fro m the sponsor CRP to allow the inadvertent ly enro lled patient to 
continue in the study  with or wi thout treatm ent wi th invest igational product.
7.1.3. Permanent Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include:
Parti cipation in the stu dy needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Subject Decisio n
othe patientrequests to be wi thdrawn from  the study
7.1.4. Patients Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a schedul ed visit or were otherwise 
unable to be fo llowed up by  the si te.
I1F-MC-RHBQ Clinical Protocol Page 45
LY24398218.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study procedures and their timing (including 
tolerance limit s for timing).   Appendix 3 lists the laboratory  tests that will be performed for this 
study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of rece ipt of confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessments 
8.1.1.1. Static Physician Globa l Assessment of Genitalia
The sPGA of Genitalia is the clinician’s determination of the patient’s psoriasis lesio ns’ overall 
severit y in the genital area (labia majora, labia minora, and perineum in females; penis, scrotum, 
and perineum in males) at a given t ime point.  Overall, le sions are categori zed by descript ions for 
elevation, ery thema, and scaling.  It is not necessary  that all  3 criteria be fulfilled.  The sPGA of 
Genitalia score is based on a combinat ion of ery them a and the secondary  features (plaque 
elevation and/or scal e).  Since ery thema is the m ost robust finding, it should be the dominant 
feature influencing the sPGA o f Genitalia rating in the majorit y of cases.   For the analysis o f 
responses, the patient’s psoriasis is assessed as clear (0), minimal (1), mild (2), mode rate (3), 
severe (4), or very  severe (5).
8.1.2. Secondary Efficacy Assessments 
8.1.2.1. Clinician Reported Assessments
8.1.2.1.1. Modified Genital Psoriasis Area and Severity Index
The m GPASI was adapted from the standard PASI by  Bissonnette et al. (2008) and Ry an et al . 
(2015) for use in male and female genital psoriasis patient s.  The m easure is the clinician’s 
determinat ion of the patient’s psoriasis severit y in the genital regio n (labia maj ora, l abia minora, 
and perineum in females; penis, scrotum, and perineum in males) at a given time po int yielding 
an overall score of 0 for no psoriasis to 72 for the most severe disease.  The scoring index 
incorporates the degree of ery thema, induration, and scaling of the genital plaques as well as 
erosi on, fissure, and/or ul cer as a produ ct of the genital area invo lved.  Severit y is rated for each 
characterist ic on a 0 to 4 scale (0 for no invo lvement up to 4 for severe involvement including 
erosi on, fissure, and/or ul cer).  The area of invo lvement for the ent ire genital area, excluding th e 
inguinal area, is graded on a 0 to 6 scale (0 for no invo lvement; up to 6 for 90% to 100% 
involvement).
I1F-MC-RHBQ Clinical Protocol Page 46
LY24398218.1.2.1.2. (Overall) static Physician Global Assessment
The sPGA is the physician’s determination o f the pati ent’s psori asis lesi onsoverall at a given 
time poin t.  The sPGA is recommended as an endpoint to assess efficacy in the treatment of 
psori asis (EMA 2004).  Overall, lesio ns are categorized by descript ions for indurati on, ery thema, 
and scaling.  For the analysis of responses, the patient’s psoriasis is asse ssed as cl ear (0), 
minimal (1), mild (2), moderate (3), severe (4), or very severe (5).
8.1.2.2. Patient Reported Assessments
The patient -reported questionnaires will be administered according to the Schedule of Activit ies
(Appendix 2 ) in countries where the questionnaires have been translated into the native language 
of the region and linguist ically validated.
8.1.2.2.1. Genital Psoriasis Symptoms Scale
The GPSS is a patient -administered assessment of 8symptom s:  itch, pain, discomfort, stinging, 
burning, redness, scaling , and cracking .  Respondents are asked to answer the questions based on 
their psori asis symptom s in the genital area .  Genit al area is defi ned as the l abia maj ora (outer 
lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, 
scrotum , and perineum (area between the penis and anus) for males. 
Num eric rating scale s(NRS) are used to assess the self -repor ted overall severit y of each of the 
8symptom sindividually in the genital area on an11-point hori zontal  scale anchored at 0 (no)
and 10 (worst imaginable) . The overall severit y for each individual symptom from patient's 
genital psori asisis indicated by  select ingthe number from 0 to 10 that best describes the worst 
level of each symptom  in the genital area in the past 24 hours.   
An e-diary willbe used to collect 
these patient rated assessments during the first 12 weeks; thereafter, patients will answer these 
question
sonly at scheduled study  visitsusing the same recall period as used for the e-diary.The 
GPSS can be co mpleted within 1 minute by patients. It will be co mpleted before the patient’s 
clinical examinat ion;before the patient receives any  text or test results; and before the patient’s 
healt h, health data ,or em otions are discussed. The instructions for completion are embedded 
within the GPSS questionnaire for patients to read before responding to the items.Thesympto m 
severit y score s, ranging fro m 0 to 10, are the value sof the selected number sindicated by  the
patient on the instrument’s horizontal scale.  Each of the 8individual items will receive a score 
of 0 to 10 and will be reported as itemscores for i tch, pai n, disco mfort, stinging, burning, 
redness, scaling, and cracking.  In addit ion, a total score ranging from 0 (no genital psoriasis 
symptoms) to 80 (worst imaginable genital psoriasis symptoms) will be reported.
8.1.2.2.2. Genital Psoriasis Sexual Impact Scale
The GPSIS i s a patient reported outcome measure to evaluate the impact of genital psoriasis 
symptoms on sexual act ivity.  Respondents are asked to answer the questions based on their 
psori asis symptom s in the genital area.   Geni tal area i s defined as the labia majo ra (outer lip), 
labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, 
scrotum , and perineum (area between the penis and anus) for males.  The definit ion of sexual 
activit y is not limited to intercourse and includes activi ties such as m asturbati on.  The 
instructi ons for com pletion are embedded within the GPSIS questionnaire for patients to read 
before responding to the items.    
I1F-MC-RHBQ Clinical Protocol Page 47
LY2439821The GPSIS consists of 3 items that include 2 subscales on avo idance of sexual activit y (Sexual 
Activity Avoidance Subscale) as well as the worsening of genital psoriasis symptoms during or 
following sexual act ivity (Impact of Sexual Act ivity on Geni tal Psoriasis Symptoms Subscale ). 
The Sexual Act ivity Avoidance Subscale includes items 1 and 2 .  Item  1 asks whether the 
patientt has been sexually act ive in the past week.  If a patient selects “no due to reasons other 
than my genital psoriasis ,” they  do not answer any addi tional questi ons on the scale and do not 
receive a score on the Sexual Act ivity Avoidance Subscale.  If a patient responds “no due to my 
genital psoriasis” on GPSIS item 1, this receives a score of “5” (equivalent to always avo id 
sexual activit y due to genital psoriasis on item 2) on the Sexual Act ivity Avoidance Subscale.  
For patients who are sexually  active, a response of never, rarely , som etimes, and often on item 2 
receive a score of 1, 2, 3, and 4, respectively, on the Sexual Activit y Avoidance Subscale.  The 
Sexual Act ivity Avoidance Subscale ranges from 1 (never) to 5 (alw ays) avoi d sexual act ivity.  
The Im pact of  Sexual Activit y on Genital Psoriasis Symptoms Subscale score includes only the 
score for GPSIS item 3.  Those patients who report as being sexually  active on the GPSIS i tem1 
are given the opportunit y to respond to item 3.  Item  3 asks the patientto select a response of 
very low or not at all  (1) to very  high (5) to reflect the level (degree) of worsening of genital 
psori asis symptom s following sexual act ivity.  
No total  score i s calculated for the GPSIS.
During the first 12 weeks, patients will use an e
-diary , using a recall period of 1 week, and the 
response for each item uses a Likert scale.  T hereafter, study  parti cipants will answer these 
questions only at scheduled study  visits using the sam e 1-week recall period as used for the 
e-diary.
8.1.2.2.3. Sexual F requency Question naire
The SFQ is a patient reported outcome measure to evaluate the impact of genital psoriasis 
symptoms on sexual frequency .  It consists of 2 items that assess the impact of genital psoriasis 
sympt oms on the frequency  of sexual act ivity.  Respondents are asked to answer the questions 
based on their psoriasis symptoms in the genital area.  Genital area is defined as the labia majora 
(outer lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; 
penis, scrotum , and perineum (area between the penis and anus) for males.  The definit ion of 
sexual activit y is not limited to intercourse and includes activit ies such as masturbation.  
Item 1 asks how m any times the patient engaged in sexual act ivity in the past week with 
response options of none/zero (2), once (1), and two or more (0).  
Item 2 assesses how often genital psoriasis symptoms limited the frequency o f sexual activit y 
with response opti ons ranging fro m 0 (never) to 4 (always).  
The individual item scores of the SFQ are reported separately.  No total score is calculated for 
the SFQ. 
The instructions for complet ion are embedded wit hin the SFQ quest ionnaire for patients to read 
before responding to the items.  Duri ng the first 12 weeks, patients will use ane-diary, using a 
I1F-MC-RHBQ Clinical Protocol Page 48
LY2439821recall period of 1 week, and the respon se for each item uses a Likert scale.  T hereafter, study 
participants will answer these quest ions only  at schedul ed study  visits using the same 1 -week 
recal l period as used for the e-diary.
8.1.2.2.4. Patient ’sGlobal Assessment of Genital Psoriasis
The Pati ent’s Gl obal Assessment of Genital Psoriasis (PatGA -Genital) is a patient -administered, 
single- item scale on which pat ients are asked to rank, by circling a number on a 0 to 5 NRS, the 
severit y of their genital psori asis “today ” from 0 (clear), no genital psori asis; to 5 (severe).
8.1.2.2.5. Dermatology Life Quality Index
The DLQI is a simple, patient -administered, 10 question, validated, qualit y-of-life quest ionnaire 
that cove rs 6 dom ains:  symptoms and feelings, daily  activi ties, leisure, work and school, 
personal relat ionships, and treatment.  Response categories include “not at all,” “a litt le,” “a lot,” 
and “very  much,” wi th corresponding scores of 0, 1, 2, and 3, respectiv ely, and “not relevant” 
responses scored as “0 ”.  Totals range fro m 0 to 30 (less to more impairment ). A DLQI total 
score of 0 to 1 is considered as having no effect on a patient ’s HRQoL, and a 5 -point change 
from baseline is considered clinically relevant (Basra et al. 2008).
8.1.2.2.6. Medical Outcomes Study 36 -Item Short -Form Health Survey 
The Short- Form  (36) Heal th Survey ( SF-36) is a 36 -item, patient -completed m easure desi gned to 
be a short, mult ipurpose assessment of healt h in the areas of physical func tioning, rol e
-physical , 
role-emotional, bodily pain, vitalit y, soci al functioning, m ental  heal th, and general healt h.  The 
2overarching do mains of mental well -being and physical well -being are captured by  the mental  
component summary  (MCS )scores and phys ical com ponent summary (PCS), respectively .  The 
summary scores range fro m 0 to 100, with higher scores indicat ing better levels of funct ion 
and/or better health.  Items are answered on Likert scales o f varying lengths.  The SF -36 acute 
versio n will be use d, which has a 1 -week recall period (SF -36 Heal th Survey Update [WWW]).
8.1.3. Exploratory Efficacy Assessments
8.1.3.1. Clinician Reported Assessments
8.1.3.1.1. (Overall) Psoriasis Area and Severity Index
The PASI is an accepted primary efficacy  measurement for thi s phase of devel opment of 
psori asis treatm ents (EMA 2004).  The PASI combines assessments of the extent of body -surface 
involvement in 4 anatomical regio ns (head, trunk, arms, and legs) and the severit y of 
desquamat ion (scaling), ery thema, and plaque induration/infil tration (thi ckness) in each regi on, 
yielding an overall score from 0 for no psoriasis up to 72 for the most severe disease 
(Fredri ksson and Pettersson 1978).  The PASI has been the most frequent ly used endpo int and 
measure of psoriasis severit y in clinical trials (EMA 2004; Menter et al. 2008).  A clinically 
meaningful response is a PASI 75, which represents at least a 75% decrease (improvement) fro m 
the baseline PASI score.  Higher levels o f clearance (PASI 90), as well as co mplete resol ution of  
psori asis (PASI 100), have beco me addit ional endpoints because of the increasing recognit ion of 
the associ ation of higher clearance wit h greater health -related qualit y of life (HRQoL) (Puig 
2015).
I1F-MC-RHBQ Clinical Protocol Page 49
LY24398218.1.3.1.2. Percentage of Body Surface Area
The invest igator will evaluate the pe rcentage invo lvement of psoriasis on each pat ient’s BSA on 
a continuous scale fro m 0% (no invo lvement) to 100% (full invo lvement), in which 1% 
corresponds to the size of the patient’s hand (including the palm, fingers, and thumb) ( Van 
Voorhees et al. 2009).
8.1.3.1.3. Fitzpatrick Skin Type Assessmen t
The Fitzpatrick Skin Ty pe is a skin classificat ion system that classifies the ty pical  response of 
different ty pes of  skin to ultravio letlight.  Ty pes range fro m the very  fair (Ty pe I) to the very  
dark (Ty pe VI).
8.1.3.1.4. Binary Q uestions on Psoriasis Location
8.1.3.1.4.1. Overall
Studying psoriasis invo lvement in the face, pubis, inguinal creases , gluteal  cleft, and perianal 
area i s of considerable interest for patients.  These are locat ions that bear high potential for 
stigmat ization and negat ive impact on qualit y of life.  In addit ion, it is important to confirm that 
associ ation of psori asis on nail s, scalp, axilla e, and inframammary  foldsthat have been 
correl ated wi th geni tal involvement in past studies (Ry an et al . 2015).  To this end, binary
responses (yes/no) will be noted at baseline, Week 4, 12, 
24, 52, or ETV whether the patient 
currently has visible psori asis on face, inframammary  fold, axilla, scalp, nail, pubis, perianal 
region,gluteal  cleft and inguinal creases .
8.1.3.1.4.2. Genital
The specific locat ion of psori asis in the genital area may  different ially impact patients in terms of 
sexual avo idance and frequency as well as physical disco mfort and pain.  To this end, binary  
questions (y es/no) will be asked at each study  visit whether the pati ent current has visible 
psori asis in wom en on l abia minora, l abia maj ora, and /orperineum and in men on the penis
(glans
and/orshaft ), scrotum, and /orperineum.
8.1.3.1.5. Binary Questions on Characteristics
8.1.3.1.5.1. Genital
Publicat ions related to genital psoriasis note that fissure, erosion, and ulcers may be present in 
the genital area.  These characterist ics may increase the pain and disco mfort of genital psoriasis 
and a lso si gnificant ly impact sexual function and qualit y of life.  Fissure, erosion, and ulcer are 
assessed co llectively on the mGP ASIbut are not ident ified individually on the scale.  To better 
understand which specific characterist ics impact patients with p soriasis, information on presence 
of these characterist ics will be recorded on the eCRF.  Binary  questi ons (y es/no) will  be asked at 
each study  visit regarding presence of fissure, erosion, and ulcer in the genital area (labia minora, 
labia majora ,and per ineum in female pat ients and penis, scrotum ,and perineum in male patients).
8.1.3.1.5.2. Perianal/Gluteal Cleft
Little informat ion is available regarding perianal characterist ics in pat ients with psori asis, and 
better understanding is needed.  Fissures, abscess, ulcer , and skin tags may  be present in the 
perianal area/gl uteal  cleft but have not been well studied in pat ients with psori asis.  However, 
perianal disease m ay significant ly impact qualit y of life and add to di scomfort/pain rel ated to the 
I1F-MC-RHBQ Clinical Protocol Page 50
LY2439821disease.  To thi s end, binary  questi ons (y es/no) will  be asked peri odically at study  visit s 
regarding presence in the perianal area of fissure, abscess, ulcer, and skin tags and in the gluteal 
cleft of fissure.
8.1.3.2. Combined Clinician/ Patient Reported Assessment
The patient -reporte d portion of  the questionnaire will be administered according to the Schedule 
of Activities(Appendix 2 ) in countries where this porti on of  the questionnaire hasbeen 
transl ated into the nat ive language of the regi on and linguist ically validated.
8.1.3.2.1. Comprehensive Assessment of the Psoriasis Patien t
An assessment of psoriasis severit y, combining both clinician (exam) and pat ient-evaluat ion 
(patient reported outcome [PRO] ; visual analog scale) to determine severit y of overall plaque 
psori asis as well as several subindices (scalp, nail, palmar -plantar , inverse, and genital).  Each 
area i s scored as 0 to 20 (0 to 10 for clinician assessment plus 0 to 10 for the higher of the 
2PROs).  For this study, we will assess only the genital severit y index.   The genital severit y 
score will range from 0 (clear/no impact) to 20 (severe genital psoriasis/worst imaginable pain 
and/or unable to be int imate at all).
8.1.3.3. Patient Reported Assessment
The patient -reported questionnaire will be administered according to the Schedule of Act ivities
(Appendix 2 ) in countries where the questionnaire hasbeen translated into the nat ive language of 
the region and linguist ically validated.
8.1.3.3.1. Touch Avoi dance Numeric Rating Scale
The Touch Avoidance Numeric Rat ing Scale is a self -administered, single item scale that 
assesses touch avo idance over the past 2 weeks due to the look or feel of the patient’s skin.  The 
item is rated on scal e of 0(not at all) t o 10 (very  much).
8.1.4. Appropriateness of Assessments
8.1.4.1. Static Physician Global Assessment of Genitalia
The sPGA of Genitalia is a versi on of thesPGA scal e used in Lilly’s Phase 3 ixekizumab clinical 
trials that has been modified for the assessment of genital involvement as noted above
(Secti on8.1.2.1.2 ).  The instruction set directs clinicians to specifically  evaluate pl aque l esion 
severit y in the geni tal area rather than the ent ire body .  Instrument scoring is based on the 
ident ical categories and similar category  descripti ons of  the sPGA scale but has been revised to 
reflect the importance of ery thema in the presentation of genital psoriasis .  The modifications to 
the scale were established with input from an Expert Consensus Development panel as well as
clinical experts in genital psoriasis fro m 3countri es.
8.1.4.2. Modified Genital Psoriasis Area and Severity Index
The mGPASI was adapted from the standard PASI by  Bissonnette et al. (2008) for use in male 
patients wi th geni tal psori asis and l ater by  Ryan et al . (2015) for use in male and female genital 
psori asis patients.  The PASI was modified to include erosion , fissure ,and ulcer as part of the 
clinical assessment in order to capture some of the addit ional symptom s that m ay be present in 
genital psoriasis as described above.  The mGPASI has been used to measure treatment effect in 
I1F-MC-RHBQ Clinical Protocol Page 51
LY2439821an open -label treatment study  of male pat ients with geni tal psori asis (Biss onnette et al . 2008), as 
well as to measure severit y of genital invo lvement in a recent cross -sectional study  of male and 
female patients with genital psoriasis (Ryan et al. 2015).  Ryan et al. (2015) found that p atients 
with increased severit y of geni tal disease, as measured quantitatively by the mGPASI, had more 
significant impairment of qualit y of life, independent of overall disease severit yfor all subject ive 
patient reported qualit y of life asse ssments, including the Relationship and Sexualit y Scale 
(RLSS ), Center for Epidemio logic Studi esDepressi onScale (CED -S),and DLQI and was the 
only objective psori asis measure which showed a significant correlat ion to all of these PROs .  
Thesestudiesdemonstrated the utilit y of the mGPASI in quantifying the objective severit y of
genital psoriasis for use in future studies.
8.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered re lated to the invest igational 
product or the study , or that caused the patientto discontinue the invest igational product before 
completing the study.  The patientshoul d be f ollowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluatio n, or is reasonably  explained.  The frequency  of follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
An AE is defined as any untoward medical occurrence in a pat ient or clinical invest igation 
subject administered a pharmaceut icalproduct that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (invest igational) product, whether or not related to the medicinal 
(invest igational) product .  Lack of drug effect is not an AE in clinical studies, because the 
purpose of the clinical study  is to establish treatment effect .
After the ICF is signed, study site personnel will record via el ectroni c data entry (eCRF) the 
occurrence and nature of each patient’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  In addit ion, site personnel  will 
record via eCRF any change in the condit ion(s) and any  new condi tions as AEs . Invest igators 
shoul d record thei r assessment of the potential relatedness of each AE to protocol procedure, 
investigat ional product, via eCRF .
The invest igator decides whether he or she interprets the observed AEs as reasonably possibly 
related to the invest igational product, study  device, study  procedure, to disease, or other 
concomitant treatment or pathologies. To assess the relati onship of the AE s, the fo llowing is 
defined:
I1F-MC-RHBQ Clinical Protocol Page 52
LY2439821Reasonably Possibly Related :Reasonable possibilit y that there i s a cause and effect 
relationship between the investigational product, study  device, and/or study  procedure 
and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational product is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent. 
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that results in 1 of the f ollowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately  life-threatening or result in death 
or hospitalization but m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above.
If an SAE occurs after signing the ICF , but pri or to receiving investigat ional product, i t needs to 
be reported ONLY if it is considered reasonably possibly related to study procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o fthe event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all follow -up SAE 
inform ation.
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator learns of any  SAE, incl uding a death, at any  time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
I1F-MC-RHBQ Clinical Protocol Page 53
LY24398218.2.2. Adverse Events of Special Interest
The fo llowing adverse events of special interest (AESIs) will be used to determine the safet y and
tolerabilit y of ixekizumab over the range of doses selected for this clinical study .
AESIs for ixekizumab are :
cytopeni as (leukopenia, neutropenia, and thrombocy topeni a)
liver funct ion test changes/enzyme elevat ions (ALT, AST, bilirubin, and alkaline 
phosphatase)
infect ions
inject ion-site reacti ons
allergic reactions/hypersensit ivities
cerebrocardiovascular events
malignancie s
inflammatory  bowel  disease 
depressio n 
Sites will provide details on AEs as instructed on the eCRF .  Invest igators will also educate 
patients and/or caregivers about the symptoms of systemic allergic/hypersensit ivity react ions and 
will provide instructi ons on the management and reporting of these reactions .  Blood sam ples
will be co llected as soon as possible for any  patient who experiences an AE of a potenti al 
systemic allergic/hypersensit ivity react ionduring the study  as judged by the invest igator.  These 
samples may  be tested forADAs ,other laboratory  tests needed to elucidate the cause of the
allergic /hypersensi tivity react ion, and /or ixekizumab serum concentration .
Data on preferred terms associated with cerebrocardi ovascular events (defined as de ath, cardi ac 
ischemic event including MIand hospitalizat ion for unstable angina, hospitalizat ion for heart 
failure, serious arrhy thmia, resuscitated sudden death, cardiogenic shock, coronary  
revascularization procedure, stroke/transient ischemic attack, p eripheral revascularization 
procedure, peripheral arterial event, and hospitalization for hy pertensi on) will be collected, and 
these events and any deaths will be adjudicated by  an external  Clinical  Events Commi ttee (CEC) 
made up of a chairperson, 2 cardio logists, and a neurologist .  The role of the CEC is to 
adjudicate these defined clinical events in a blinded, consistent, and unbiased manner throughout 
the course of a study .  The purpose of the CEC is to ensure that all events that have been reported 
areevaluated uniformly by a single group (the CEC).
8.2.2.1. Suspected Unexpected Serious Adverse Reactions
Lilly has procedures that will be fo llowed for the recording and expedited reporting of SUSARs 
that are consistent with glo bal regulat ions and the associated d etailed guidances.
I1F-MC-RHBQ Clinical Protocol Page 54
LY24398218.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and produ ct improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
8.3. Treatment of Overdose
Refer to the IB.
8.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, ECGs should be co llected locally at screening according to the Schedule of 
Activities (Appendix 2 ).  Electrocardi ograms should be recorded according to the study  specific 
recommendat ions included in theManual of Operations for the stud y.  
Electrocardiograms will be interpreted locally by a qualified physician. Any clinically 
significant findings from ECGs that result in a diagnosis and that occur after the patient receives
the first dose o f the invest igational treatment should be reported to Lilly  or its designee as an AE 
via eCRF .
8.4.2. Vital Signs
For each patient, vital signs measurements should be conducted according to the Schedule o f 
Activities (Appendix 2 ) and f ollowing the study  specific recommendations included in the 
Manual o f Operati ons for the study .  At baseline (Week 0) and Visit 7 (Week 12), BP and pulse 
shoul d be measured pri or to administration of the investigational product and again 
approximately  1 hour post -administration.
Any clinically  significant findings from vital signs me asurement that resul t in a di agnosis and 
that occur after the patient receives the first dose of study  treatm ent shoul d be reported to Lilly or 
its designee as an AE viaeCRF .
8.4.3. Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 3 ) shoul d be conducted according to the 
Schedule of Act ivities (Appendix 2 ). 
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product should be reported to Lilly or its 
designee as an AE via eCRF .
I1F-MC-RHBQ Clinical Protocol Page 55
LY24398218.4.4. Physical Examination
For each patient, a complete physical examinat ion should be conducted according to the 
Schedule of Act ivities (Appendix 2 ) and fo llowing the study  specific recommendat ions included 
in the Manual o f Operati ons f or the study .  
Any clinically  significant findings from a complete physical examinat ion that result in a 
diagnosis and that occur after the patient receives the f irst dose of study  treatm ent shoul d be 
reported to Lilly  or its designee as an AE viaeCRF .
8.4.5. Chest X -Ray and Tuberculosis Testing
A posteri or-anterior view chest x -ray will be obtained, unless the x -ray or resul ts from a chest 
x-ray obtained wi thin 6 m onths pri or to the study  are available.  The chest x -ray or resul ts will  be 
reviewed by  the invest igator or designee to exclude patients with active TBinfect ion.  
In addit ion, pati ents will  be tested at screening as indicated on th e Schedule of Activities
(Appendix 2 ) for evi dence of act ive or latent TB indicated by a posit ive tuberculin PPD skin test 
response ( ≥5 mm indurat ion, between approximately  2 and 3 days after test application, 
regardl ess of BCG vaccinat ion history ).  In countries where an Interferon -Gamma Release Assay
(Quant iFERON ®-TB Gold test , and/or T-SPOT ®)is available and in the judgment of the 
investigator pre ferred as an alternat ive to the PPD skin test for the evaluation of TB infect ion, it 
may be used instead of the PPD test (posit ive tests excluded) and may be read locally.  If the 
Quant iFERON ®-TB Gol d test is indeterminate , or the T-SPOT ®is invalid or borderline ,1 retest 
is allowed.  If the retest for the QuantiFERON ®-TB Gol d test is indeterminate , or the retest for 
the T-SPOT ®is invalid or borderline , then the patient is excluded from enrollment in the study .
Patients wi th docum entati on of  a negat ivetest result within 3 months prior to baseline (Week 0; 
Visit 2) do not need a TB screen at Visit 1.  Documentation of this test result must include a 
record of the size of the induration response (<5 mm indurat ion).  A PPD test recorded as 
negat ive wit hout document ing the size of indurat ion will result in a retest.
However, patients with a PPD skin test ≥5 mm indurati on or a posit ive Quant iFERON ®-TB 
Gold or posi tive T-SPOT ®test at screening, but no other evidence of act ive TB may be 
rescreened 1 time and may be enro lled without repeating a PPD or QuantiFERON ®-TB G oldtest 
or T-SPOT ®if the fo llowing condi tions are met:
after receiving at least 4 weeks of appropriate latent TB infection (LTBI) 
therapy , with commit ment by  the patient and the investigator for the pati ent to 
complete a full course of prophylaxis for TB
with no evidence o f hepatotoxicit y (ALT/AST must remain ≤2 times ULN) 
upon retesting of serum ALT/AST prior to randomizat ion.  Such patients must 
complete appropri ate LTBI therapy  during the cou rse of the study  in order to 
remain eligible
meet all other inclusio n/exclusio n criteria for partici pation  
I1F-MC-RHBQ Clinical Protocol Page 56
LY2439821If rescreening occurs within 6 months of the screening chest x -ray, there is no necessit y for 
repeat of chest x -ray for consi dering enrollment.   
Patients with positive TB test results on file :  Patients with prior history  of a posi tive TB test 
shoul d not have a TB test perform edat Visi t 1.  Docum entati on of  this history  and of at l east 4 
weeks of appropriate latent TB treatment prior to baseline (Week 0, Visit 2) is required for study  
eligibilit y.  Pati ents who have a documented history  of com pleting an appropriate TB treatment 
regimen with no history  of re-exposure to TB since their treatment was completed and no 
evidence of active TB are eligible to parti cipate in the study .  Pati ents who have had household 
contact wi th a person wi th active TB are excluded, unless an appropri ate and docum ented course 
of prophylaxis for TB was completed.
Any clinically  significant findings from chest x -rays and/or tubercul osis testings that resul t in a 
diagnosis and that occur after the patient receives the first dose of study  treatm ent shoul d be 
reported to Lilly  or its designee as an AE viaeCRF .
8.4.6. Immunogenicity
Samples for immunogenicit y testing, including samples that may be analyzed for ixe kizumab 
concentration will be co llected at time points indicated in the Schedule of Act ivities (Appendix 
2).Addit ionally,blood sam plesfor potenti al immunogenici ty testing will be collected, as soon 
aspossible, fo r any  patient who experi ences a potent ia
l systemic allergic/hypersensit ivity 
reacti on during the study  as judged by  theinvest igator.  Thesesample smay be tested for ADAs, 
ixekizumab serum  concentrati on, and/or other l aboratory  tests needed to elucidate the cause of 
the allergic/hypersensit ivity react ion.
8.4.7. Quick Inventory of Depressive Symptomatology —Self-Report 
(16Items)
QIDS -SR16 is a self -administ ered, 16 -item instrument intended to assess the existence and 
severit y of symptom s of depressio n as listed in the American Psychiatric Associat ion’s 
Diagnostic and Stati stical Manual of Mental Disorders, 4th Edit ion (DSM -IV) (APA 1994).  A 
patient is asked to consider each statement as it relates to the way  they have felt for the past 
7days.  There i s a 4-point scale for each item ranging fro m 0 to 3.  The 16 items corresponding 
to 9 depression domains are summed to give a single score ranging fro m 0 to 27 , with higher 
scores denoting greater symptom severit y.  The domains assessed by  the instrum ent include:  (1) 
sad m ood, (2) concentration, (3) self -criticism, (4) suicidal ideat ion, (5) interest, 
(6)energy/fatigue, (7) sleep disturbance (init ial, middle, and late inso mnia or hypersomnia), 
(8)decrease/increase in appetite/weight, and (9) psycho motor agi tation/retardati on.  Addi tional 
inform ation and the QIDS -SR16 questions may be found at the Universit y of Pittsburgh 
IDS/QIDS i nternet page [WWW].   A QIDS -SR16 assessment will be taken at times indicated in 
the Schedule of Act ivities (Appendix 2 ).
I1F-MC-RHBQ Clinical Protocol Page 57
LY24398218.4.8. Safety Monitoring
Lilly willperiodically  revie w evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
If a study  patient/subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL 
≥2X ULN, clinical and laboratory  monitoring should be init iated by  the invest igator.  Detail s for 
hepat ic monitoring depend upon the severit y and persistence of observed laboratory  test 
abnorm alities.  To ensure patient/subject safet y and com ply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP regarding collect ion of sp ecific reco mmended 
clinical informat ion and fo llow-up laboratory  tests.   See Appendix 4 .
8.4.8.1. Neutropenia
During treatment with investigational product , pati ents wi th neutrophil counts <1500 cells/ L 
(<1.50x 103/µL or <1.50 GI/L) should be managed for neutropenia as fo llows:
<500 cells/ L (<0.50x 103/µL or <0.50 GI/L) , see Discontinuation Criteria 
(Secti on 7.1)
≥500 cells/ L and <1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor 
≥0.50 GI/L and <1.00 GI/L), see Discont inuation Criteria (Section 7.1)
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor 
≥1.00 GI/L and < 1.50 GI/L), and the patient has a concurrent infect ion that 
requi res systemic ant i-infect ive therapy (for example, ant ibiotic, ant ifungal agent, 
antiviral agent):  
oThe dose of invest igational product should be withheld, the patient should 
receive appropri ate m edical care, and a repeat test for neutrophil count should 
be perform ed wi thin 4 weeks from  knowl edge of  the init ial report.  If the 
repeat neutrophil count has returned to ≥1500 cells/ L (≥1.50x10 3/µLor 
≥1.50x10 3/µL)and the infect ion has reso lved o r is resolving, the pati ent m ay 
resum e dosing of invest igational product and evaluation at scheduled visits.  If 
the neutrophil count remains ≥1000 cells/ L and <1500 cells/ L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L), 
investigat ional pr oduct should cont inue to be withheld and a repeat neutrophil 
count should again be performed within another 4 weeks.  If, after 2 repeat 
tests, the neutrophil count still remains ≥1000 cells/ L and <1500 cells/L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/ L and <1.50 GI/L), and:
the infect ion has not fully  resolved, the pati ent will be discontinued from 
the study treatm ent and continue safet y follow up .
the infect ion has reso lved, the patient may resume dosing and evaluat ion 
at scheduled visit s.  However, i f resum ption of dosing is not deemed 
appropriate by  the investi gator, the pati ent will be discontinued fro m the 
study treatm ent and continue safet y follow up .
I1F-MC-RHBQ Clinical Protocol Page 58
LY2439821≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and 
<1.50 GI/L), and the patient has no concurrent infection that requires systemic 
anti-infective therapy (for example, ant ibiotic, ant ifungal agent, antiviral agent):  
oDosing may continue, and a repeat neutrophil count should be performed 4 to 
8weeks from k nowl edge of the init ial report.  Testing may be at a regularly 
scheduled visit or at an unscheduled visit, as necessary .
Repeat testing should be performed at 4 -to 8-week intervals unt il the 
neutrophil count has returned to ≥1500 cells/L (≥1.50x10 3/µL or
≥1.50 GI/L) .  If the patient has 3 or more postbaseline neutrophil counts of 
≥1000 cells/L (≥1.00x10 3/µL or ≥1.00 GI/L) and <1500 cells/L 
(<1.50x10 3/µL or <1.50 GI/L) , no value of <1000 cells/L (<1.00 x10 3/µL or 
<1.00 GI/L) , and no postbaseline infecti on requi ring sy stemic ant i
-infect ive 
therapy , the pati ent m ay cont inue or resume further evaluation at scheduled 
visits, as deemed appropriate by  the invest igator.
If a patient without init ial concurrent infection develops an infection that requires system ic 
anti-infective therapy, then the patient should be managed as indicated above for patients with 
concurrent infect ion.  
If, at the last scheduled visit or ETV , the pati ent’s neutrophil count is <1500 cells/ L 
(<1.50x10 3/µL or <1.50 GI/L) and less than the pati ent’s baseline neutrophil count, the 
following measures should be taken:
Patients with Concurrent Infection:   If there is a concurrent infect ion that requires 
systemic anti -infect ive therapy, the patient should receive appropriate medical 
care and a repeat test for neutrophil count should be performed at least Q4W (or 
sooner as appropriate) until reso lution of infect ion.  Upon resolut ion of infect ion, 
the neutrophil count should be mo nitored using the required study  visits in the 
Post-Treatment Foll ow-Up Peri od (Peri od 4) design at Visits 801 (4 weeks 
post-resolut ion of infect ion), 802 (8 weeks after Visit 801), and 803 (if necessary; 
12weeks after Visit 802); addit ional visits may be requi red depending on the 
degree of neutropenia. 
Patients withou t Concurrent Infection:   If there is no concurrent infection that 
requi res systemic ant i-infect ive therapy, the neutrophil count should be monitored 
using the required study  visits in the Post -Treatment Follow -Up Peri od (Peri od 4) 
design, Vi sits 801 (4 wee ks post -ETV or l ast regularly  scheduled visi t), 802, and 
803 (if necessary ); addi tional visits may be requi red depending on the degree of 
neutropeni a.
For Visit 801 and subsequent visits , the fo llowing m onitoring applies:
As long as a pati ent’s neutrophil count is <1000 cells/ L (<1.00x10 3/µL or 
<1.00 GI/L) at any fo llow up visit, the patient should return for visit s at l east 
Q4W (may  requi re unscheduled visits).  
I1F-MC-RHBQ Clinical Protocol Page 59
LY2439821As long as a pati ent’s neutrophil count is ≥1000 cells/ L and <1500 cells/ L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L) at any 
follow
-up visit, the patient should return for addit ional visit(s) at least every 
4to 8 weeks (may  requi re unscheduled visits).  
If,at Vi sit 802 or Visit 803, the pati ent’s neutrophil count is ≥1500 cells/ L 
(≥1.50x10 3/L or ≥1.50 GI/L) or greater than or equal to the patient’s baseline 
neutrophil count (whichever is lower), the patient’s participat ion in the study 
will be considered complete unless the invest igator deems addit ional 
follow-up m ay be necessary .  
If, at Vi sit 803, the pati ent’s neutrophil count remains <1500 cells/ L (<1.50x10 3/µL or 
<1.50 GI/L) and less than the patient’ s baseline neutrophil count, or if the invest igator deems 
additional follow-up m ay be necessary , the invest igator in consultat ion with Lilly, or qualified 
designee, will determine the appropriate management of the patient and the appropriate timing of 
additional contact(s) or vi sit(s).
8.4.8.2. Hepatitis B Monito ring
Patients that are HBcAb+ at screening, regardless of other hepat itis B testing results , will have a 
serum  HBV DNA specimen obtained to be analyzed by the central laboratory.  Such p atients that 
aredetermined to be HBV DNA negat ive (undetectable) may be enrolled into the study  with 
requi red HBV DNA mo nitoring every  3to 4 months during treatment and 12 weeks after the last 
dose of ixekizumab .  Pati ents that are found to be HBV DNA posit ive (detectable) at screening 
will be excluded fro m the trial.  
Ifthe resul t of any subsequent HBV DNA testing is posit ive, the patient must be discont inued 
from the study  treatm ent, should cont inue safet y follow up, and should receive appropriate 
follow-up m edical care, including consideration for antiviral therapy. Aspecialist physician in 
the care of patients with hepat itis (for example, infectious disease or hepatologist subspecialists) 
shoul d be consul ted and potenti ally start antiviral therapy prior to discont inuat ion of any  
immunosuppressant or immuno modulatory  therapy (including invest igational drug). Timing of 
discontinuat ion from the study  and of any  immunosuppressant /immuno modulatory therapy  
(including investigat ional product) needs to be based on the recommendat ions of the consult ing 
specialist physician in conjunct ion with the invest igator and medical guidelines/standard of care.
8.4.8.3. Hypertension
Patients who experience changes in BP (sy stolic BP at ≥160 mm Hg plus ≥20 mm Hg increase 
from baseline [Week 0; Visi t 2]; and/or diastolic BP at ≥100 mm Hg plus ≥10 mm Hg increase 
from baseline) on 2 consecutive visit s should receive intervent ion for the m anagement of 
hypertensio n.  See Section 7.1for the discont inuation criterion related to hypertension.
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ),blood samples of 
approximately  4 mL each will be co llected to determine the serum  concentrati ons of ixekizumab.   
These blood samples for PKanalysis are matched to the timing of samples for the assessment of 
I1F-MC-RHBQ Clinical Protocol Page 60
LY2439821immunogenicit y.  These samples are designed to be taken at trough , that is, immediately prior to 
dosing. It is expected that these PK samples will allow sufficient descript ion of ixekizu mab PK 
profiles at steady  state throughout the study .
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.   
The actual  date and time (24-hour clock time )of each sampling will be recorded.
Drug concentration inform ation that mayunblind the study  will not be reported to invest igat
ive 
sites or blinded personnel unt il the study has been unblinded.
Samples co llected for PK analysis will be tested at a laboratory approved by Lilly or its designee. 
Concentrations of imm unoreactive ixekizumab in human serum will be determined by  a 
validated m ethod.
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .
8.6. Pharmacodynamics
Not applicable
8.7. Genetics
Ablood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Appendix 2 ) where l ocal regulati ons and ERBs allow.  These samples are not being 
collected to create a biobank for conducting unspecified disease or populat ion genet ic research 
either now or in the future.
Samples will  notbe used to conduct unspecified d isease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to ixekizumab and to 
investigate genet ic variants though t to pl ay a rol e in psoriasis and/or associate dautoimmune 
condi tions.  Assess ment of variable response may include evaluat ion of AEs or differences in 
efficacy .  These studi es may  include but are not limited to the IL-17 and IL -23 family and 
receptor and signaling pathways, to evaluate their associat ion with observed response to 
ixekizumab .
All pharmacogenet ic samples will be coded with the patientnumber.  These samples and any 
data generated can be linked back to the patient only by the invest igator site personnel.  Samples 
will be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if local r egulati ons and/or ERBs impose shorter time limits, at a facilit y 
selected by  the sponsor.  This retent ion peri od enables use of new techno logies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed unt il later 
in drug development or when the drug is co mmercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequenc ing, geno me wide association studies, candidate gene studies, and epigenetic analyses.  
I1F-MC-RHBQ Clinical Protocol Page 61
LY2439821Regardless of techno logy utilized genoty ping data generated will be used only  for the specific 
research scope described here. 
8.8. Biomarkers
Serum , plasma, and mRNA sample s for nongenet ic bio marker research will be co llected at the 
times specified in the Schedule of Act ivities (Appendix 2 )where l ocal regulati ons and ERBs 
allow.
Samples will  be used for research on the drug target, disease process, pathways associated with 
psori asisand/or associ ated autoimmune condit ions, mechanism  of action of  ixekizumab , and/or 
research method or in validat ingdiagnost ic tools or as say(s) related to psoriasis and/or associated 
autoimmune condit ions.Proteomic, gene -expression, genomic, epigenetic, or metabolomic 
analysis may  be perform ed on these samples.
All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to the patient only by the investigator site personnel.  Samples will 
be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  15 years after the l ast patientvisit for the study , or f or a 
shorter period if local regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  This retent ion peri od enables use o f new techno logies, response to regulatory  
questions, and invest igation of varia ble response that may  not be observed unt il later in drug 
development or when the drug is commercially available.
8.8.1. Sam ples for Immunogenicity Research
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to det ermine ant ibody  producti on against ixekizumab as specified in the Schedule o f 
Activities (Appendix 2 ).The actual date of each sampling will be rec orded at the study  
site.Immunogenicit y will be assessed by  a validated assay  designed to perform  in the presence 
of ixekizumab.  Ant ibodies may be further characterized and/or evaluated for their abilit y to 
neutralize the activit y of ixekizumab.
Sampleswill be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests related to 
ixekizumab .
8.8.2. Samples for Genital C andida Testing 
Where local regulat ions and ERBs allow, genital skin swab samples for Candida testing will be 
collected and may  be used to determine presence of Candida at baseline. Swabs will be 
collected from labia majora in wo men and gl ans penis in men .
Deficiency or inhibit ion of IL -17 has been linked to mucocutaneous candidiasis (Puel et al. 2011; 
Cosent yxpackage insert, 2015 ). In the Phase 3 trials of ixekizumab in the treatment of psoriasis, 
Candida infections were observed in approximately 3% of patients who received ixekizumab , 
I1F-MC-RHBQ Clinical Protocol Page 62
LY2439821some of which invo lved the genital area . None of the Candida infect ions were SAE s or l ed to 
discontinuat ion of study  treatm ent. Noneof the vulvo vaginal candidiasis cases were considered 
severe ,and none were considered related to invest igational product by invest igators.  
Candida skin swabs will be tested at baseline for exploratory purposes to better understand 
colonizat ion withCandida spp.ofthe genitalia of patients with psoriasis that invo lves the genital 
area.  In general, these test results are not clinically informat ive without a clinical diagnosis of 
candidiasis, andthe resul ts will not be shared wit h investigators.  
Ifan invest igator believes it is 
clinically indicated for patient management (per the local standard of care ),then he/she may 
choose to take an addit ional skin swab to be evaluated per local procedures .
8.9. Health Economics
Not a pplicable
I1F-MC-RHBQ Clinical Protocol Page 63
LY24398219.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
The total sample size for the study  will be approximately 146 pati ents randomized at 1:1 ratio in 
the Blinded Treatm ent Period to ixekizumab Q2W and placebo (73 patients per treatment group). 
No pri or sPGA of Geni talia (primary  outcom e measure) data was available at the time of 
planning this study  to gui de sam ple size and power cal culat ions because no bio logic drug has 
been evaluated in a well -controlled clinical trial to date in patients with genital psoriasis .  
Theref ore, based on the relevance and impact of sexual impairment in genital psoriasis, data 
from the assessment of DLQI Item 9 (How much has y our skin caused any  sexual difficul ties?) 
outcom es in the ixekizumab Phase 2 and Phase 3 studies were used to calculate the sam ple size .  
Sample size was calculated assuming sexual impairment rates of 2% and 20% in the ixekizumab
Q2W and placebo treatm ent groups, respectively. With the seassumed rates, a sample size of 
146 (73 per treatment group) is likely  to achi eve 94%power, based on a 2-sided Fisher's exact 
test at 0.05 level o f significance.
9.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany .
Categorical data for baseline variables will be summari zed as frequency counts and percentages .  
Continuous data for baseline variables will be summarized in using the mean, standard deviation, 
minimum, maximum, median, and number of observat ions.
Any change to the data analysis methods described in the protoc ol will requi re an amendment 
ONLY if it changes a principal feature of the protocol.  Any
 other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropriate.
Com plete details of the planned analyses will be documented in the statistical analysis plan 
(SAP).
General Considerations for Analyses during Period 2 ( Blinded Treatme nt Period)
Com parisons of ixekizumab Q2W dosing versus placebo will be perform ed for all  outcom e 
variables in Period 2.  Baseline will be defined as the last available value before the first 
inject ion of the investigational product for both efficacy and sa fety analyses.  In most cases, this 
will be the measure ment recorded at Week 0 (Visit  2).  For efficacy measures, if the pat ient does 
nottake any  inject ion, the last available value on or prior to randomizat ion date will be used .  
Change from baseline at a parti cular visi t will be calculated as the value at that visit minus the 
baseline value .  For safet y analyses using a baseline period, the baseline period is defined as the 
time fro mVisit 1 to the date/time of the first injection.
For outcom e measure s that are not collected at each postbaseline visit, data may exist at visit s 
where the outcom e measure was not scheduled to be co llected, due to ETVs .  In these situat ions, 
I1F-MC-RHBQ Clinical Protocol Page 64
LY2439821data from  the ETVs that does not correspond to the planned collection schedule wil l be excluded 
from anymixed-effects models for repeated measures ( MMRM) analysis.  However, the data 
will st ill be used in other analyses, including shift analyses, change fro m baseline analyses using
last observat ion carried forward ( LOCF ) imputati on met hod, and other categorical analyses .
9.3. Anal ysis Population
Intent -toTreat Population :  The intent-to-treat ( ITT
)populat ion consists of all rando mized 
patients .  Even if the pat ients are not administered the assigned treatment, do not receive the 
correct treatment, or otherwise do not follow the protocol, they  will be analyzed according to the 
treatm ent group to whi ch they  were assigned. 
Safety Population :  The safet y popul ation is defined as all rando mized pat ients who received at 
least 1 dose of study  treatm ent. Patients will be analyzed according to the dosing regimen to 
which they  were assigned.
Open -Label Treatment Population :  The open -label treatm entpopul ationconsists of all 
rando mized patients w ho received at least 1 dose of study treatment during Period 3and have 
entered the Open -Label Treat ment Period.  Patients will be analyzed according to the treatment 
group to whi ch they  were assigned in Period 2 .  All analyses for Period 3 (Open -Label Treatment 
Period) will be conducted on this analysis popul ation.  
Post-Treatment Follow -Up Population :  The post-treatment follow up popul ationconsists of
all rando mized pat ients who received at least 1 dose of study  treatment duri ng Peri od 2 and have 
enter ed the Post -Treatment Fo llow-Up Peri od.  Patient data will be summarized according to the 
treatm ent group to whi ch they  were assigned in Peri od 2.  Safet y analyses for Period 4 
(Post -Treatment Follow -Up Peri od) will  be conducted on this analysis popul ation.
9.3.1. Missing Data Imputation
Themethods for imputati on of  missing data to be used in this study are described below.
Nonresponder Imputation (NRI)
Analysis of categorical efficacy and healt h outcome variables will be performedusing NRI
method.   Patients will be considered nonresponders if they do not meet the clinical response 
criteria or have missing clinical response data at the time point of analysis.  Randomized patients 
without at l east 1postbaseline observation will also be defined as nonr esponders for the NRI 
analysis.
Last Observation Carried Forward (LOCF)
LOCF m ethod will  be used to impute missing data for only the maj or secondary continuous 
outcom e variable .  For patients having missing data at a visit, the last nonmissing postbaseline
observat ion before themissing data will be carried forward to the corresponding time po intof 
evaluat ion.  Rando mized pat ients without at l east 1postbaseline observation will not be included 
in LOCF analyses.
Modified Baseline Observation Carried Forwar d (mBOCF) 
I1F-MC-RHBQ Clinical Protocol Page 65
LY2439821An mBOCF analysis will be performed on all continuous efficacy and healt h outcom e variables.
For pati ents di scont inuing invest igational product due to an AE, the baseline observation will be 
carried forward to the corresponding primary  endpoint for evaluation.   For pati ents di scont inuing 
investigat ional product for any  other reason, the l ast nonmissing postbaseline observat ion before 
discontinuat ion will  be carri ed forward to the corresponding time point of evaluat ion.
Randomized patients without at least 1 postbaseline observat ion will not be included for 
evaluat ion with the except ion of pat ients discont inuing study  treatm ent due to an AE.
In addit ion to NRI , mBOCF ,and L OCF, other imputation methods may be used as deemed 
appropriate.
9.3.2. Adjustment for Multiple Comparisons
A multipletesting strategy  for the primary  and themajo r secondary  endpoint will be 
implemented to control the family -wise t ype I error rate at a 2 -sided α level of 0.05. The 
following primary and m ajorsecondary endpo intwill be sequent ially tested in the fo llowing 
order to com pare ixekizumab Q2W v ersus placebo ,using the primary analysis method .
Prima ry–Proporti on of  patients achieving sPGA of Genitalia (0,1) at Week 12
Major Secondary  –Mean change from baseline in the genital psoriasis itch NRS item 
within the GPSS at Week 12
The primary  endpoint will be tested at 2-sided α = 0.05. If the test for primary endpo int is 
significant, then the test for the major secondary endpo intwill be performed. Otherwi se the 
testing will stop. 
There will be no adjust ment for multiple com parisons for any  other analyses.
9.4. Treatment Group Comparability
9.4.1. Patient Disposition
Adetailed description o f patient di sposi tion will be provi dedat the end of the study .  
All pat ients 
who discont inue from the study  treatment and the study  will be ident ified, and the extent of their 
participat ion in the study will be reported.   Patient disposit ion will  be summarized for each 
treatm ent period and will include reasons for discont inuat ion.  The reasons for discont inuat ion 
during Blinded Treatm ent Peri od (Peri od 2) will be com pared between treatm ent groups using 
Fisher ’s exact test.
9.4.2. Patient Characteristics
Baseline characteri stics, clinical ,and heal th outcome measurements will be summarized for each
popul ation –ITTand Open -Label  Treatm ent.  Baseline characteri stics will include gender, age, 
age category , wei ght, race, geographic regio n, baseline disease severit y, durati on of  disease, 
previous nonbio logic systemic therapy , and previ ous bi ologic therapy .  Baseline clinical and 
PRO measurements will include sPGA of Geni talia score, mGPASI total score, overall sPGA,   
overall PASI, BSA, GPSS total and i tem scores (incl uding Geni talPsoriasisItch NRS) , DLQI 
I1F-MC-RHBQ Clinical Protocol Page 66
LY2439821total score, GPSIS subscales ,SFQ items, PatGA -Genital, Touch avoidance NRS, SF -36, QIDS -
SR16, and CAPP .
Treatment group comparisons will be conducted using Fisher’s exact test for categorical data and 
an analysis o f variance (ANOVA) model with treatment as a factor for continuous data.
9.4.3. Concomitant Therapy
Previous and concomitant medicat ions (including concomitant topical products such as 
emollients and other nonprescription topical products) will be summarized for patients who enter 
each treatment period and will be presented by  World Heal th Organizat ion Anatomic 
Therapeut ic Class (WHOATC) Level 4 and WHO preferred term.   Treatment group comparisons 
in Period 2 will be conducted using Fisher’s exact test.
9.4.4. Treatment Compliance
Treatment compliance wit h investigational product will be summarized for patients who enter 
Period 2.  A patient will be considered co mpliant overall for each study  period if he/she misses 
no m ore than 20% of the expected doses, does not miss 2 consecutive doses, and does not over-
dose (that is, take more injections at the same t ime po int than specified in the protocol).  
Proporti ons of pat ients com pliant overall will be compared between treatment groups during 
Period 2 using Fisher’s exact test.
9.5. Primary  and Secondar y Anal yses
9.5.1. Primary Analyses
Categorical
oTreatment comparisons of catego rical efficacy  and heal th outcom e variables will 
be performedusing a l ogistic regressio n model with treatm ent and BSA category  
as factors, using NRI method. 
Continuous
oThe primary  analyses for all cont inuous efficacy and healt h outcome variables 
will be performedusing MMRM .  The model will include treatment, baseline 
BSA category , baseline value, visit, treatment -by-visit interaction ,and 
baseline -by-visit interacti on as fixed factors.  The covariance structure to model 
the within-patient errors will be unstructured.  If the unstructured covariance 
matri x result s in a l ack of convergence, the heterogeneous Toeplitz covariance 
structure, followed by the heterogeneous aut oregressive covariance structure will 
be used. The Kenward- Roger m ethod will be used to estimate the denominator 
degrees of freedo m. Type III tests for the least-square ( LS)means will be used 
for the stati stical co mpar ison; the 95% confidence interval ( CI) will  also be 
reported. Treatment group comparisons at all visits up to Week 12 will be tested.  
If the unstructured covariance matrix results in a lack of convergence, the 
heterogeneous Toeplitz covariance structure, fo llowed by  the heterogeneous 
autoregressive covariance structure, fo llowed by the com pound symmetry  will be 
I1F-MC-RHBQ Clinical Protocol Page 67
LY2439821used. This order is specified according to a decreasing number of covariance 
param eters in the structure.
9.5.2. Secondary Analyses 
Categorical
oSecondary  analysis on the categorical effi cacy variables will be conducted using a 
Fisher’s exact test.  
oAcategori cal, pseudo -likelihood -based MMRM for categorical repeated measure s 
analysis may  also be perform ed for the primary endpoint of sPGA of 
Genitalia (0,1).  The details of the analysis model will be presented in the SAP.
Continuous
oSecondary  analyses for treatment comparisons on contin uous outcom e vari ables 
willbe conducted using an analysis o f covari ance (ANCOVA) model and LOCF 
or mBOCF imputation method s. The ANCOVA model will include treatment, 
baseline BSA category ,and baseline value.  Type III sums of squares for the LS 
means will be used for the statistical com parison; the 95% CI will be reported.
9.5.3. Exploratory Analyses
The exploratory  outcom e measures will be a nalyzed using similar ana lysis methods described 
above. Com plete detail s will  be docum ented in the SAP.
9.6. Safety Analyses
Safety will be assessed by summarizing and analyzing AEs including adjudicated
cerebrocardiovascular events , QIDS -SR16, laboratory  analy tes incl uding neutrophil counts and 
immunogenicit y, vital signs, and concomitant medicat ions.The durati on of  exposure will also 
be summarized.
The primary  safety analyses will focus on comparisons of ixekizumab Q2W versus placebo in 
Period 2.  Treatment comparisons o f categori cal safet youtcom e variables will be performed
using Fisher's exact test . Treatment comparisons of cont inuous safety outcome variables will be 
perform edusing ANCOVA wit h treatment and baseline value in the model.    
Summaries of safet y data collected during the Open -Label  Treatment Period and Post -Treatment 
Follow-Up Peri od will  be presented separately . The categori cal safety  measures will  be 
summarized wit h incidence rates. The mean change of the continuous safet y measures will be 
summariz ed by  visits. 
Unless otherwise specified, the baseline for safet y analyses in the Open-Label Treatment Period
is defined as the last nonmissing asse ssment on or prior to Week 12 (Visit 7) . Unless otherwise 
specified, the Post-Treatment F ollow -Up Period B aseline is defined as the last nonmissing 
assessment on or prior to Week 52 (Visit 12) or ETV .
9.6.1. Adverse Events
Adverse events are classified based upon the Medical Dict ionary for Regul atory  Activities 
(MedDRA). A TEAE is defined as an event that first occu rred or worsened in severit y after the 
I1F-MC-RHBQ Clinical Protocol Page 68
LY2439821first dose of study  treatm entand on or prior to the date of the last visi t within the treatm ent 
period. Both the date/time of the event and the date/time of the dose ( ie,inject ion) are 
considered when determining TEAEs .  For each TEAE, the severit y is recorded according to the 
patient’s or phy sician’s perceived severit y of the event (mild, moderate, or severe). A follow-up
emergent adverse event (FEAE) is defined as an event that first occurred or worsened in seve rity 
after the date of Week 52 (Visit 15) or the ETV. For events that are gender specific, the 
deno minator and computation of the percentage will only include patients from the given gender.
An overall summary o f AEs will be provided for each treatment pe riod.  TEAEs , SAEs including 
deaths, AEs that led to invest igational product discontinuat ion, and AEs by maximum severit y 
and relationship to invest igational product will be summarized by  MedDRA system  organ class 
(SOC) and preferred term (PT). TEAEs will also be summarized by PTsorted by  decreasing 
frequency  within SOC for all TEAEs, TEAEs by  maximum  severi ty, and TEAEs consi dered 
possibly  related to investigational product .
FEAEs (all, by maximum  severi ty, and FEAEs possibly related to invest igational p roduct by the 
investigator), SAEs including deaths, AEs that lead to study discont inuat ionwill be summarized 
by MedDRA SOC and PT or by  PT f or the Post -Treatment Follow -Up Peri od (Peri od 4).
In addit ion to general safet y param eters, safet y inform ation on specific topics of special interest 
will also be presented. Potential AESI swill be i dentified by a standardized MedDRA query  
(SMQ) or a Lilly defined MedDRA PT list ing.
9.6.2. Clinical Laboratory Tests
Laboratory  assessments will be presented as mean changes f rom baseline and as incidence of 
treatm ent-emergent abnormal, high, or low laboratory  values .  Shift tables will be presented for 
selected parameters.
For categorical lab tests :  
oTreatment -emergent abnormal value = a change from normal at all baseline vis its 
to abnormal at any  time postbaseline.
For continuous lab tests :  
oTreatment -emergent high value = a change from a value less than or equal to the 
high limit at all baseline visits to a value greater than the high limit at any  time 
postbaseline.
oTreatment -emergent low value = a change from a value greater than or equal to 
the low limi t at all  baseline visi ts to a value l ess than the l ow limi t at any  time 
postbaseline.
9.6.3. Vital Signs, Physical Findings, and Other Safety Evaluations
Vital signs will  bepresented as m ean changes from baseline and as incidence of abnormal values 
and will be summarized for both pre dose and postdose at Week 0 (Visit 2) and Week 12 
(Visit 7), as applicable.
I1F-MC-RHBQ Clinical Protocol Page 69
LY2439821The m aximum  postbaseline QIDS -SR16 total  score will be summarized by treatm ent, and shift 
table will be produced for the change from baseline in QIDS -SR16 total score category.
Other covariate data, including body  weight, will  be descri ptively summarized by treatment 
groups.  Further analyses may be performed comparing the treatm ent groups.
9.7. Pharmacokinetic/Pharmacodynamic Analyses
Observed ixekizumab serum concentrations will be summarized by  visits and corresponding time 
when sampling occurred.
As appropri ate, the PK and the exposure -response relat ionship between ixekizuma b exposure 
and clinically  important efficacy  measures (for example, sPGA or mGP ASI) may  be expl ored 
using graphical methods and/or a modeling approach. If a modeling approach is taken, data may 
be co mbined with data fro m other ixekizumab studies if approp riate. 
The potential impact of immunogenicit y on ixekizumab exposure and/or efficacy responses may
be evaluated by graphical assessments, as appropriate, to compare drug exposure or efficacy
responses between ADA negat ive and ADA posit ive pat ients at corresponding visits, or before
and after ADA development for patients who developed ADA .  Both treatment -emergent only
and all ADA posit ive/negative pat ients may be explored .  A similar approach may be taken if
patients beco me neutralizing ant i-drug antibody (NAb) positive.
Addit ional analyses m ay be performed upon receipt of the data .  Data from this study may be
combined wit h data from previous efficacy studies for addit ional popul ation PK and/or exposure
efficacy  modelling if deemed appropri ate.
9.8. Other Analyses
9.8.1. Subgroup Analyses
To assess c onsistency  of resul ts am ong the 2 subpopul ations determined by baseline BSA 
category  (<10% versus ≥10% baseline BSA invo lvement) , subgroup analysis will be conducted 
onsPGA of Geni talia (0,1) using the ITT populat ion.
Other s ubgroups that may be evaluated include gend er, age, weight, race, andgeographi c regi on. 
Detailed descript ion of the subgroup variables will be provided in the SAP.
A logistic regressio n model with treatm ent, subgroup, and the interact ion of subgroup by  
treatm ent included as factors will be used. The subgroup-by- treatm ent interacti on will be tested 
at the significance level of 0.10. Treatment group differences will be evaluated within each 
category  of the subgroup using Fisher’s exact test, regardl ess of whether the interaction is 
statist ically significant. Missing data will be imputed using NRI .  If any group within the 
subgroup is less than 10% of the total populat ion, only  summaries of the efficacy data will be 
provi ded ( that is noinferent ial testing will be perform ed).  
Addit ional subgroup analyses on efficacy or safet ymay be perform ed as deemed appropriate.
I1F-MC-RHBQ Clinical Protocol Page 70
LY24398219.8.2. Immunogenicity Analyses
The analyses of ADA effects will be conducted on all evaluable patients within the defined 
safet y popul ation.  Evaluable pat ients will be defined as either a) patients with an evaluable 
baseline sample and at l east 1 evaluable postbaseline sample (that is, sample after administration 
of investigational product ); or b) patients with no evaluable baselin e sample whose evaluable 
postbaseline samples were all ADA negat ive.  A treatment -emergent posi tive ant i-drug ant ibody  
(TE-ADA+) patient will be defined as any occurrence o f a greater than or equal to 4-fold or 
2dilution increase in immunogenicit y titer over the baseline t iter.  This is equivalent to an 
increase in titer to ≥1:10 , in the case of a negat ive result at baseline .  
The frequency and percentage (incidence) of pat ients with posi tive, negat ive, or inconc lusive 
ADA at baseline and patients with posit ive, negat ive, or inconclusive TE -ADA postbaseline will 
be summarized by treatment group.  Addit ional summarizat ions for patients who are TE -ADA +
will be done for patients who are TE -ADA persistent or transient positive; pat ients who are NAb 
positive, negative, or inconclusive; and for ADA titers.
Assessment of immunogenicit y with respect to safety  will include com parison of patients who 
experience TEAEs of systemic allergy/hypersensit ivity and of inject ion-sitereacti ons and also 
develop treatment -emergent ADA positive status with patients who experience the same t ypes of 
TEAEs but who remain treatment -emergent ADA negat ive.  ADA titers will  also be evaluated in 
patients who experience these events.
9.9. Interim Anal yses
Aninterim database lock and the unblinding of the sponsor will occur ,and the analysis will be 
perform ed at the time (that is, a cut -off date) the last patient completes Visit 7(Week 12), 
completes ETV ,or discont inues from the Blinded Treatment Per iod (Period 2) .  This interim 
database lock will include all data collected by  the cut -off date including data fro m the 
Open -Label  Treatm ent Peri od and follow
-up data from  patients who have begun Post -Treatment 
Follow-Up Peri od(Peri od 4) .  Because the stu dy will still be ongoing for the Open- Label 
Treatment Period and the Post -Treatment Fo llow-Up Peri od at the time of this database lock, the 
analysis will be referred to as an interim analysis.  This interim analysis includes the final 
analysis for the Blinded Treatment Period (Peri od 2) of the study ; therefore, there is no alpha 
adjustm ent due to thi s interim analysis.   There will be no data monitoring committee .
A final database lock will occur after the Post -Treatment Follow -Up Peri od is com pleted.   
Site-level unblinding will occur after final database lock is complete.
Unblinding details will be specified in a separate unblinding plan docum ent.
I1F-MC-RHBQ Clinical Protocol Page 71
LY243982110.Study  Governance Considerations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Proces s
10.1.1. Informed Consent
The invest igator is responsible for ensuring:
that the patientunderstands the potential risks and benefits of part icipating in 
the study
that informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of 
investigat ional product.
answering any quest ions the patientmay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the trial
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the in vestigative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be pr ovided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guide lines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Gui deline s
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party .
I1F-MC-RHBQ Clinical Protocol Page 72
LY243982110.1.4. Investigator Information
Physicians with a specialt y indermatol og yor other specialt ies wit h appropriate experience 
(private practice, universit y, psori asis r esearch centers) will parti cipate as investigators in this 
clinical trial.
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and cond uct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Report Signature
The CSR coordinat ing invest igator will sign the final CSR for this study , indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
The CSR coordinat ing invest igator will be selected by the sponsor.  If this investigator is unable 
to fulfill this funct ion, another invest igator will be chosen by Lilly to serve as the CSR
coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instructi on on the protocol, the complet ion of the eCRFs, and 
study  procedur es.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
cond uct a qualit y review of the database
In addit ion, Lilly or its representatives willperiodically check a sample of the patientdata 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
I1F-MC-RHBQ Clinical Protocol Page 73
LY2439821representatives, and/or regul atory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem  and an electronic source system will be used in this study .  
The site ma intains a separate source for the data entered by  the si te into the sponsor -provided 
electroni c data capture system.   Some or all o f a pati ent’s data will be direct ly entered into the 
eCRF at the time that the informat ion is obtained.  In instances where d irect data entry  is not 
used, the si te will maintain source documentation in the trial files, and the patient’s data will be 
transcribed into the eCRF.  Paper documentation provided by the patientwill serve as the source 
docum ent,including a SDAL , that will be identified and documented by each site in that site’s 
study  file.  
In thi s study , pati ent-rated scales/quest ionnaires will be collected at office visits ( andat home) 
directly via an electronic patient -reported outcome (ePRO) tablet device as part of an 
ePRO/Clinical Outcome Assessment (COA) system.  Data entered into the ePRO/COA system 
will serve as the source data.
ePRO records are stored at a third party  site.  Investigator sites will have continuous access to the 
source data during the study a nd will receive an archival copy  at the end of the study  for 
retenti on.
Any data collected withinthe ePRO instrument will serve as the source data and will be 
ident ified and documented by each site in that site’s study file .
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system.  Data will subsequent ly be transferred fro m the central  
vendor to the Lilly generic labs system.
Data from co mplaint forms submitted to Lilly will be e ncoded and stored in the global product 
complaint m anagement sy stem .
10.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
I1F-MC-RHBQ Clinical Protocol Page 74
LY243982110.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I1F-MC-RHBQ Clinical Protocol Page 75
LY243982111.References
[AAD] American Academy of Dermatology  Work Group, Menter A, Korman NJ, Elmets CA, 
Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim 
HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the 
management of psori asis and psori atic arthrit is: section 6. Guidelines of care for the treatment 
of psori asis and psori atic arthrit is: case- based presentations and evidence -based conclusio ns. 
JAm Acad Dermatol . 2011;65(1):137 -174.
[APA] American Psychiatr icAssoci ation.Diagnosti c and statistical manual  of mental  disorders 
(DSM -IV).4th Ed.Washington DC: APA; 1994.
Andreassi L, Bilenchi R. Non -infect ious inflammatory  genital lesio ns. Clin Dermatol . 
2014;32(2):307 -314. 
Barchino -Ortiz L, Suárez -Fernández R, Lázaro -Ochaita P. Vulvar inflammatory dermatoses. 
Actas Dermosifiliogr . 2012 ;103(4):260 -275.
Basra MK A, Fenech R, Gatt RM, Salek MS, Finlay  AY. The Derm atology Life Qualit y Index 
1994- 2007: a comprehensive review of va lidation data and clinical result s. Br J Dermatol . 
2008 ;159(5):997 -1035.
Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerabilit y of topical tacrolimus oint ment for 
the treatment of male genital psoriasis. J Cutan Med Surg . 2008;12(5):230 -234.
Buechner SA. Commo n skin disorders of the penis. BJU Int . 2002 ;90(5):498 -506.
[CDA] Canadian Dermatology  Associ ation. Canadian guidelines for the management of plaque 
psori asis. June 2009. Available at: http://www.dermatology.ca/wp -
content/uploads/2012/01/cdnpsoria sisguidelines.pdf . Accessed: October 1, 2015.
Cosent yx[package insert]. East Hanover, New Jersey: Novartis Pharmaceut icals Corporation; 
2015
[EMA] European Medicines Agency. Committee for medicinal products for human use (CHMP). 
Guideline on clinical invest igation of medicinal products indicated for the treatment of 
psori asis. November 2004. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guidelin
e/2009/09/WC50
0003329.pdf . Accessed November 09 , 2015.
Farber EM, Nall L. Genital psoriasis. Cutis . 1992;50(4):263 -266.
Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results fro m a European 
survey. J Eur Acad Dermatol Venereol. 2005;19(suppl  3):2 –6.
Fredri ksson T, Pettersson U. Severe psoriasis --oral therapy  with a new retino id. Dermatologica. 
1978;157(4):238 -244.
Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med . 1995;332(9):581 -588.
Griffit hs CE, Reich K, Lebwohl M, van de K erkhof P, Paul  C, Menter A, Cameron GS, Erickson 
J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nicko loff BJ, Papp 
K; UNCOVER -2 and UNCOVER -3 invest igators. Com parison of ixekizumab wit h etanercept 
I1F-MC-RHBQ Clinical Protocol Page 76
LY2439821or placebo in m oderate -to-severe ps oriasis (UNCOVER -2 and UNCOVER -3): results from 
two phase 3 rando mised trials . Lancet . 2015 ;386(9993):541 -551. 
Guglielmetti A, Conlledo R, Bedoy a J, Ianiszewski F, Correa J. Inverse psoriasis invo lving 
genital skin fo lds: successful therapy  with dapsone. Dermatol Ther (Heidelb) . 2012;2(1):15.
[ISSVD] International Societ y for the Study  of Vulvovaginal Disease (ISSVD) Patient 
Inform ation Co mmit tee.Revised 2014 . Available at: http://issvd.org/wordpress/wp
-
content/uploads/2014/12/VULVAR -PSORIASIS.pdf . Accessed October 1, 2015.
Jemec GB, Baadsgaard O. Effect of cyclosporine on genital psoriasis and lichen planus. J Am 
Acad Dermatol . 1993;29(6):1048- 1049.
Krueger JG, Fretzin S, Suárez -Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, 
Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. IL- 17A is essential for cell 
activat ion and inflammatory  gene ci rcuits in subjects wi th psoriasis. J Allergy Clin Immunol. 
2012;130(1):145 -154.
Linden KG, Weinstein GD. Psoriasis: current perspectives with an emph asis on treatment. Am J 
Med. 1999;107(6):595- 605.
Martín Ezquerra G, Sánchez Regaña M, Herrera Acosta E, Umbert Millet P. Topical tacrolimus 
for the treatm ent of  psori asis on the face, genitalia, intertriginous areas and corporal plaques. 
JDrugs Dermatol .2006;5(4):334 -346.
Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque 
psori asis: an abridged Cochrane systematic review. J Am Acad Dermatol . 2013;69(5):799 -807.
Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Ke rkhof PC, van Rossum MM. 
Genital psoriasis: a questionnaire -based survey on a concealed skin disease in the Netherlands. 
J Eur Acad Dermatol Venereol . 2010;24(12):1425-1430.
Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkho f PC, van Rossum MM. Genital 
psoriasis: a system atic literature revi ew on this hidden skin disease. Acta Derm Venereol . 
2011(a);91(1):5 -11. 
Meeuwis KA, de Hullu JA, van de Nieuwenho f HP, Evers AW, Massuger LF, van de Kerkho f 
PC, van Rossum MM. Qualit y of life and sexual health in pat ients with geni tal psori asis. Br J 
Dermatol . 2011(b);164(6):1247- 1255. 
Meeuwis KA, van de Kerkho f PC, Massuger LF, de Hullu JA, van Rossum MM. Patients’ 
experience o f psori asis in the genital area. Dermatology . 2012;224(3):271- 276.  
Meeuwis KA, de Hullu JA , Inthout J, Hendriks IM, Sparreboom EE, Massuger LF, van de 
Kerkho f PC, van Rossum MM. Genital psoriasis awareness program: physical and 
psycho logical care for patients with genital psoriasis. Acta Derm Venereol . 
2015;95(2):211 -216. 
Menter A, Gottlieb A, Feldman SR, VanVoorhees AS, Leonardi CL, Gordon KB, Lebwohl M, 
Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the 
management of psoriasis and psori atic arthrit is:section 1. Overview of psoriasis and 
guidelines o f care for the treatm ent of psori asis wit h bio logics. J Am Acad Dermatol . 
2008;58 (5):826-850.
I1F-MC-RHBQ Clinical Protocol Page 77
LY2439821Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, 
Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R, American Academy o f 
Derm atology. Guidelines o f care for the management of psoriasis and psoriat ic arthrit is. 
Secti on 3. Gui delines of care for the management and treatment of psoriasis with topical 
therapi es. J Am Acad Dermatol . 2009;60(4):643 -659.
Puel A, Cypowyj S, Bustamante J, Wrig ht JF, Li u L, Lim HK, Migaud M, Israel L, Chrabieh M, 
Audry  M, Gumbleton M, Toul on A, Bodem er C, El -Baghdadi J, Whitters M, Paradis T, 
Brooks J, Collins M, Wo lfman NM, Al -Muhsen S, Galicchio M, Abel L, Picard C, Casanova 
JL. Chronic mucocutaneous candidias is in humans with inborn errors of interl eukin -17 
immunit y. Science. 2011;332(6025):65 -68.
PuigL. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad 
Dermatol Venereol . 
2015;29(4):645 -648.
Rallis E, Nasiopoulou A, Kouskouki s C, Roussaki -Schulze A, Koumantaki E, Karpouzis A, 
Arvanit is A. Successful treatment of genital and facial psoriasis wit h tacrolimus oint ment 
0.1%. Drugs Exp Clin Res . 2005;31(4):141 -145.
Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottl ieb AB, Koo JY, 
Lebwohl MG, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in 
psori asis: opportunit ies for future studies. J Am Acad Dermatol . 2014;70 (1):146-167. 
Ryan C, Sadlier M, De Vol E, Patel M, Llo yd AA, Day  A, Lally  A, Kirby B, Menter A. Genital 
psori asis is associated with significant impairment in qualit y of life and sexual functioning. J 
Am Acad Dermatol . 2015;72(6):978 -983. 
Scott LJ, Dunn CJ, Goa KL. Ca lcipotrio l ointment. A review of its use in the management of 
psori asis. Am J Clin Dermatol . 2001;2(2):95 -120.
SF-36 Heal th Survey Update page . SF-36 web site. Available at: http://www.sf -
36.org/tools/sf36.sht ml. Accessed October 1, 201 5 .
Stern RS. Genital tumors am ong men wi th psori asis exposed to psoralens and ultravio let A 
radiation (PUVA) and ultravio let B radiat ion. The Photochemotherapy  Follow-up Study . 
NEngl J Med . 1990;322(16):1093- 1097.
Stern RS, Laird N. The carcinogenic risk of treatments for se vere psoriasis. Photochemotherapy  
Follow-up Study . Cancer . 1994;73(11):2759- 2764.
Stern RS, Bagheri S, Nicho ls K; PUVA Fo llow Up Study . The persistent risk of genital tumors 
among men treated wi th psoral en plus ul traviolet A (PUVA) for psoriasis. J Am Acad
Dermatol . 2002;47(1):33 -39.
Universit y of Pittsburgh .IDS/QIDS resource page. Available at: http://www.ids -qids.org/. 
Accessed October 1, 2015 .
Van Voorhees A, Feldman SR, Koo JYM, Lebwohl MG, Menter A. The psoriasis and psoriat ic 
arthri tis pocket gui de. Portl and: Nat ional Psoriasis Foundat ion; 2009. 
Weichert GE. An approach to the treatment of anogenital pruritus. Dermatol Ther . 
2004;17(1):129 -
133.
I1F-MC-RHBQ Clinical Protocol Page 78
LY2439821Welsh BM, Berzins KN, Cook KA, Fairley CK. Management of commo n vulval condit ions. Med 
J Aust . 2003;178(8):391 -395.
I1F-MC-RHBQ Clinical Protocol Page 79
LY2439821Appendix 1. Abbreviations and Definitions
Term Definition
ADAanti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory findi ng), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
BCGBacillus Calmette -Guérin
BPblood pressure
BSAbody surface area
blinding/masking A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, site level blinding will remain in effect until 
final database lock is complete .
A double -blind study is one in which neithe r the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received .
CEC Clinical Events Committee
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
cGMP current Good Manufacturing Practices
COA Clinical Outcome Assessment
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, dura bility, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
eCRF electronic case report form:  printed or electronic form for recording study participants’ 
data during a clinical study, as required by the protocol
I1F-MC-RHBQ Clinical Protocol Page 80
LY2439821CRP clinical research physician : Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
DLQI Dermatology Life Quali ty Index
ECG electrocardiogram
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
ETV early  termination visit
FEAE follow -upemergent adverse event
GCP good clinical practice
GPSI S Genital Psoriasis Sexual Impact Scale
GPSS Genital Psoriasis Symptom Scale
HBcAb+ anti-hepatitis B core antibody
HBV hepatitis B virus
HCV hepatitis C virus
HRQoL health -related quality of life
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
IL-17A interleukin -17A 
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the a uthorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB institutional review board
I1F-MC-RHBQ Clinical Protocol Page 81
LY2439821ITT intention to treat : The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence t hat patients allocated to a treatment group should be followed up, 
assessed ,and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive web -response sy stem
LTBI latent tuberculosis infection
LOCF last observation carried forward
LS least-square
mBOCF modified baseline observation carried forward
MedDRA Medical Dictionary for Regulatory Activities
mGPASI modified Genital PASI
MI myocardial infarction
MMRM mixed-effects model for repeated measures
NAb neutralizing anti -drug antibody
NRI nonresponder imputation
NRS numeric rating scale
PASI Psoriasis Area and Severity Index
PASI 75 75% reduction in PASI from baseline
PK pharmacokinetics
PPD purified protein derivative
PPS per-protocol set : The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PRO/ePRO patient-reported outcome/electronic patient -reported outcome
PT preferred term
PUVA psorale nandultravi olet A
Q2W every 2 weeks
Q4W every 4 weeks
QIDS -SR16 Quick Inventory of Depressive Symptomatology –Self Report (16 items)
I1F-MC-RHBQ Clinical Protocol Page 82
LY2439821QTc corrected QT interval
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen the act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study
SDAL study drug administration log
SF-36 Short -Form (36) Health Survey
SFQ Sexual Frequency Questionnaire
SOC system organ class
sPGA static Physician Global Assessment
SUSARs suspected unexpe cted serious adverse reactions
TB tuberculosis
TBL total bilirubin level
TE-ADA+ treatment -emergent positive anti -drug antibody
TEAE treatment -emergent adverse event : Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and thatdoes not necessarily have to 
have a causal relation ship with this treatment .
ULN upper limit of normal
UVB ultraviolet B
WBC white blood cell
I1F-MC-RHBQ Clinical Protocol Page 83
LY2439821Appendix 2. Schedule of A ctivities
I1F-MC-RHBQ Clinical Protocol Page 84
LY2439821Schedu le of Activities , Protocol I1F-MC -RHBQ
ScreeningBaseline 
RandomizationBlinded Treatment Period 
(Period 2)
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7
Weeks since Randomization W0 W1 W2 W4 W8 W12
Study Days -30 to -7 dV1A: 2-3 d 
post-V11 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 2d 84± 4d
Infor med consent X
Complete medical history X
Demographics a X
Sociodemographic sb X X
Physical exam ination c X X X
Perianal /gluteal cleft
characteristics examinationX X X
Inclusion/ exclusion criteria d X X
Body temperature X
Height X
Weight X X
Waist circumference X
Vital signs (BP and pulse) X Xe X X X X X e
Consumption habits f X
Concomitant medications X X X X X X X
Review preexisting 
conditions /AEsX X X X X X
Randomization X
Administer IP on site X X
I1F-MC-RHBQ Clinical Protocol Page 85
LY2439821ScreeningBaseline 
RandomizationBlinded Treatment Dosing Period 
(Period 2)
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7
Weeks since Randomization W0 W1 W2 W4 W8 W12
Study Days -30 to -7 dV1A: 2-3 d 
post-V11 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 2d 84 ± 4d
Dispense IP X X X X X
Provide SDAL gX X X X X
Collect, review, and enter data 
from SDALX X X X X
Review e-diary X X X X X
Dispense e-diary (includes GPSS , 
GPSIS ,and SFQ)X
Collect e -diary X
Clinical Efficacy/Health Outcomes
sPGA (overall) X X X X X X X
sPGA of Genitalia h X X X X X X X
PASI (overall) X X X X X X X
mGPASI i X X X X X X X
BSA X Xj X X X j X X j
Fitzpatrick skin type X
GPSS k Daily from Screening (V1) to Week 12 (V7) X
GPSIS k Weekly from Screening (V1) to Week 12 (V7) X
SFQ k Weekly from Screening (V1) to Week 12 (V7) X
PatGA -Genital X X X X X X
Touch avoidance NRS X X X X X
I1F-MC-RHBQ Clinical Protocol Page 86
LY2439821ScreeningBaseline 
RandomizationBlinded Treatment Dosing Period 
(Period 2)
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7
Weeks since Randomization W0 W1 W2 W4 W8 W12
Study Days -30 to -7 dV1A: 2-3 d 
post-V11 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 2d 84 ± 4d
SF-36 X X
DLQI X X X X X
QIDS -SR16 X X X
CAPP (genital subindex) X X
Laboratory Tests
Administer PPD/ QuantiFERON ®-
TB Gold/ T-SPOT ®lX
Read PPD X
Chest x -raym X
ECG X
HIV/HCV X
HBV n X X X
FSHo X
Serum pregnancy test p X
Urine pregnancy test q X X X X
Serum chemistry X X X X
Lipid panel r X X X
Hematology X X X X
TSH and free T4 X
I1F-MC-RHBQ Clinical Protocol Page 87
LY2439821ScreeningBaseline 
RandomizationBlinded Treatment Dosing Period 
(Period 2)
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7
Weeks since Randomization W0 W1 W2 W4 W8 W12
Study Days -30 to -7 dV1A: 2-3 d 
post-V11 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 2d 84 ± 4d
Genetic biomarker exploratory 
storage samples (DNA) sXt
Nonpharmacogenetic biomarker 
exploratory storage samples 
(serum, plasma, mRNA) sX X X X
Immunogenicity testing s,u X X X X
PK sample (trough) s,v X X X X
Candida skin swab w X
I1F-MC-RHBQ Clinical Protocol Page 88
LY2439821Open -Label Treatment 
(Period 3)ETV Post- Treatment Follow-Up
(Period 4) x
Required Follow -Up 
VisitsAs-Needed 
Follow-Up 
Visits
CRF Visit (V) Number V8 V9 V10 V11 V12 ETV y V801 V802V803 zand 
onward
Weeks since Randomization W16 W24 W28 W40 W52 LV + 4W LV + 12W LV + 24W
Study Days112 ± 
7d168 ± 
7d196 ± 
7d280 ± 
7d364 ± 
7d
Sociodemographic sb X X
Physical examination c X X X X
Perianal /gluteal cleft
characteristics examinationX X X
Weight X X
Waist circumference X X
Vital signs (BP and pulse) X X X X X X
Concomitant medications X X X X X X
Review preexisting conditions 
/AEsX X X X X X
Dispense IP X X X X
Provide SDAL g X X X X
Collect, review, and enter data 
from SDALX X X X X X
I1F-MC-RHBQ Clinical Protocol Page 89
LY2439821Open -Label Treatment
(Period 3) ETVPost- Treatment Follow -Up
(Period 4) x
Required Follow -Up 
VisitsAs-Needed 
Follow-Up 
Visits
CRF Visit (V) Number V8 V9 V10 V11 V12 ETV y V801 V802V803 zand 
onward
Weeks since Randomization W16 W24 W28 W40 W52 LV + 4W LV + 12W LV + 24W
Study Days112 ± 
7d168 ± 
7d196± 
7d280 ± 
7d364 ± 
7d
Review e-diary X
Collect e-diary X
Clinical Efficacy/Health Outcomes
sPGA (overall) X X X X X X
sPGA of Genitalia h X X X X X X
PASI (overall) X X X X X X
mGPASI i X X X X X X
BSA X X j X X X j Xj
GPSS k X X X X X X
GPSIS k X X X X X X
SFQ k X X X X X X
Touch avoidance NRS X X X X X X
SF-36 X X
PatGA -Genital X X X X X X
I1F-MC-RHBQ Clinical Protocol Page 90
LY2439821Open -Label Treatment
(Period 3) ETVPost- Treatment Follow -Up
(Period 4) x
Required Follow -Up 
VisitsAs-Needed 
Follow-Up 
Visits
CRF Visit (V) Number V8 V9 V10 V11 V12 ETV y V801 V802V803 zand 
onward
Weeks since Randomization W16 W24 W28 W40 W52 LV + 4W LV + 12W LV + 24W
Study Days112 ± 
7d168 ± 
7d196± 
7d280 ± 
7d364 ± 
7d
DLQI X X X X X X
QIDS -SR16 X X X X
CAPP (genital subindex) X X
Laboratory Tests
HBV n X X X X
Urine pregnancy test q X X X X X X
Serum chemistry X X X X X X X X
Hematology X X X X X X X X
Lipid panel r X X X X
Nonpharmacogenetic biomarker 
exploratory storage samples 
(serum, plasma, mRNA) sX X
Immunogenicity testing s,u X X X X
PK sample (trough) s,v X X X X
I1F-MC-RHBQ Clinical Protocol Page 91
LY2439821Abbreviations:  AE=adverse event; BP = blood pressure; BSA = body surface area; CAPP =Comprehensive Assessment of the Psoriasis Patient; CRF = case 
report form; d = days; DLQI = Dermatology Life Quality Index; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ETV = ear ly termination visit; 
FSH = follicle -stimulating hormone; GPSS = Genital Psoriasis Symptoms Scale; GPSIS =Genital Psoriasis Sexual Impact Scale; HBV = hepatitis B virus; 
HCV = hepatitis C virus; HIV = human immunodeficiency virus; IP = investigational product; LV= last visit; mRNA = messenger r ibonucleic acid; 
mGPA SI=modified Genital PASI; NRS = numeric rating scale; PASI = Psoriasis Area and Severity Index; PatGA -Genital =Patient’s Global Assessment of 
Genital Psoriasis; PK = pharmacokinetic; PPD = purified protein derivative; QIDS -SR16 = Quick Inventory of Depr essive Symptomatology –Self Report (16 
items); SDAL = Study Drug Administration Log; SFQ = Sexual Function Question naire ; sPGA = static Physician’s Global Assessment; T4 = thyroxine; TB = 
tuberculosis; TSH = thyroid stimulating hormone; V = study visit; W = study week.
aDemographics includes recording of year of birth, gender, ethnicity ,and race .
bSociodemographics includes recording information on marital and sexual partner status.
cOne complete physical examination (excluding pelvic, rectal, and breast examinations) will be performed at screening.  All ph ysical examinations throughout 
the study  should include a symptom directed physical as well as examination of heart, lungs, abdomen , and visual examination of the skin. 
dPatients who test positive for latent TB at screening may be rescreened (Section 8.4.5 ).  Additionally, patients who do not qualify at screening under exclusion 
criteria [34, 
38, 39, 50] may  be rescreened (1 time) as described in Section 5.3.
eAt baseline (Week 0) and Visit 7 (Week 12) , BP and pulse should be measured prior to administration of the investigational product and again approximately 
1 hour post-administration.
fHabits include recording of caffeine, alcohol ,and tobacco consumption.
gPatients will record information including the date, time, and location of administration of investigational product (for tre atment compliance), syringe number , 
who administered the investigational product, and the reason if investigational product was not fully administered in the SDAL .
hAs part of sPGA of Genitalia, the investigator will record on the eCRF (yes/no) whether psoriasis is present in women on lab ia minora, labia majora, and/or 
perineum and in men on penis (glans and/orshaft ), scrotum, and/or perineum .
iAs part of mGPASI, the investigator will record on the eCRF (yes/no) if fissure, erosion ,and/or ulcer arepresent in the genital area (defined a s labia minora, 
labia majora, perineum for female patients and on the penis, scrotum, perineum for male patients) .
jAs part of BSA, the investigator will record if psoriasis is present on the face, inframammary fold, axilla, scalp, nail, pubis, perianal region , gluteal cleft, and 
inguinal creases in the eCRF (yes/no) at baseline (Week 0), Week 4, 12, 24, 52, or ETV .
kPatients should complete the scales in the following order :  1.GPSS, 2. GPSIS, and 3. SFQ.An e -diary willbe used to collect these PROs up to and including 
Week 12 (V7); thereafter, patients will answer these questions only at scheduled study visits.  At Week 12 (V7), patients wil l complete the sescales on site 
before completion of any other assessments.
lSee Section 8.4.5 for detailed description of QuantiFERON ®-TBGold , T-SPOT ®, and PPD testing.
mA chest x -ray will be taken at screening unless one has been o btained within the past 6 months (provided the x -ray and/o r report are available for review) .
nAll patients will be tested for HBV at screening.  Patients who are HBsAg+ at screening are excluded.  Patients who are HBcAb + at screening, regardless of 
other HBsAb status, will have serum HBV DNA obtained to be analyzed by the central laboratory.  Patients that are found to be HBV DNA positive 
(detectable) at screening will be excluded from the trial.  Patients that are HBcAb+ at screening and HBV DNA negative (undetectable) may be enrolled into 
the study  with required HBV DNA monitoring ever y 3to 4months as outlined above in the Schedule of Activities during treatment and 12 weeks after the 
last dose of ixekizumab.  If the result of the HBV DNA testing is positive, the patient must be discontinued from the study treatment, should continue safety 
follow up, and should receive appropriate follow -up medical care (refer to Section 8.4.8.2 for further information regarding the timing of discontinuation).
I1F-MC-RHBQ Clinical Protocol Page 92
LY2439821oFSH test performed for women ≥40 and <60 years of age who have had a cessation of menses for at least 12 months to confirm no nchildbearin g potential 
(≥40 mIU/mL). FSH test willbe performed centrally.
pTo be performed for females of childbearing potential only.  Serum pregnancy test will be done at Visit 1 only and will be pe rformed centrally.  
qTo be performed for females of childbearing potential only.  Patients will undergo urine pregnancy self-testing at home on a monthly basis during periods 
between scheduled visits through Week 52 . During these intervisit periods, the site must call the pat ient each month to obtain her pregnancy test results.  
Additional urine pregnancy testing can be performed at the investigator’s discretion.   Patients determined to be pregnant will be discontinued from treatment 
and will no longer be administered investig ational product (see Section 7.1).
rFor the fasting lipid profile patients should not eat or drink anything except water for 12 hours prior to test . (For ETV : [1]If ETV is planned, then fasting 
lipid profile should be performed , and [2] if ETV is not planned and patient is not fasting, the lipid profile should not be performed.)
sSamples will be collected as allowed by local regulations.
tIf the DNA sample is not collected at Visit 2 (Week 0), it can be collected at Visit 3 (Week 4).
uImmunogenic ity samples may also be analyzed for ixekizumab serum concentration to facilitate in the interpretation of the immunogenicity data.  In addition, 
a blood sample will be collected, when possible, for any patient who experiences a potential systemic allergic/hypersensitivity react ion during the study as 
judged by the investigator (Section 8.4.6) .
vPK samples will be collected prior to administration of investigational product (Section 8.5)
.
wSwab from labia majora for women and glans penis for men.
xAll patients receiving investigational product must enter into Period 4and complete through Visit 802.  Patients may be followed beyond Visit 802 for 
continued monitoring of their neutrophil coun tsor for other safety reasons .
yIf a patient discontinues study treatment early, the patient will complete the ETV and then enter the Post -Treatment Follow -Up Period.
zThis visit will only occur if a patient’s neutrophil counts have not returned to the criteria defined in Section 8.4.8.1 .or for other safety reasons.
I1F-MC-RHBQ Clinical Protocol Page 93
LY2439821Appendix 3. Clinical Laboratory  Tests 
Hematology a,b Serum Chemistry a,b
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume (MCV) Chloride
Mean cell hemoglobin concentration (MCHC) Phospho rus
Leukocytes (WBC) Total bilirubin
Platelets Direct bilirubin
Alkaline phosphatase
Absolute counts of: Alanine aminotransferase (ALT/SGPT)
Neutrophils, segmented Aspartate aminotransferase (AST/SGOT)
Neutrophils, juvenile (bands) Blood urea nitrogen (BUN)
Lymphocy tes Uric acid
Monocytes Creatinine
Eosinophils Calcium
Basophils Glucose
Albumin
Other Tests a Cholesterol ( total)
Human immunodeficiency virus antibody (HIV) c Total protein
Hepatitis B Surface antigen (HBsAg) d,e
Anti
-Hepatitis B Surface antibody (HBsAb) d,e Triglycerides
Anti
-Hepatitis B Core antibody (HBcAb) d,e Gamma - Glutamyl Transferase (GGT)
Anti-Hepatitis C antibody c,d
HBV DNA c,f Lipid Panel a,h
Thyroid-stimulating hormone (TSH) and Free T4    Low Density Lipoprotein (LDL -C)
Ixekizumab serum concentration    High Density Lipoprotein (HDL)
Explo ratory  storage samples (serum, plasma, DNA, & 
mRNA)   Very  Low Density Lipoprotein (VLDL)
Pregnancy Test (serum and urine) i
Purified Protein Der ivative (PPD) g Follicle -stimulating hormone (FSH) j
I1F-MC-RHBQ Clinical Protocol Page 94
LY2439821Clinical Safety Laboratory Tests
Abbreviations:  Ab = antibody; DNA = deoxyribonucleic acid; HBcAb =anti-hepatitis B c ore antibody ; HBsAb = 
anti-hepatitis B surface antibody; HBsAb+ =positive for anti -hepatitis B s urface antibody ;HBsAg -= negative 
for hepatitis B surface antigen; HBV = hepatitis B virus; LDL -C= low density  l ipoprotein calculated; mRNA = 
messenger ribonucleic acid; RBC = red blood cells; SGOT = serum glutamic oxaloacetic transaminase ; SGPT = 
serum glutamic pyruvi c transaminase ; T4 = thyroxine; TB = tuberculosis; WBC = w hite blood cells.
aAssay ed by sponsor -designated laboratory.
bUnscheduled blood chemistry andhematology panels may be performed at the discretion of the investigator .  
cSee exclusion criteria ( Section 5.2).
dTest required at Visit 1 only to determine eligibility of patient for the study .  
eQuantitative HBsAb testing will be done in those patients who are HBsAg –, HBcAb+, and HBsAb+ at screening.  
fRefer to hepatitis B monitoring (Section 8.4.8.2 ).
gIn countries where the QuantiFERON ®-
TB Gold test or T-SPOT ®is available, it may be used instead of the PPD 
TB test and may be performed locally.
hFor the fasting lipid profile patients should not eat or drink anything except water for 12 hours prior to test .
iSerum pregnancy test (women <60 years of age who are still of childbearing potential) and urine pregnancy test 
(women of childbearing potential).  Patients will undergo urine preg nancy self -testing at home on a monthly 
basis during periods between scheduled visits until Week 52.   During these intervisit periods, the site must call 
the patient each month to obtain her pregnancy test results.  Additional urine pregnancy testing can b e performed 
at the investigator’s discretion.  Patients determined to be pregnant will be discontinued from treatment and will 
no lo nger be administered investigational product (see Section 7.1).
jWomen ≥40 and <60 years of age who have had a cessation of menses for ≥12 months will have an FSH test 
confirming nonchildbearing potential ( ≥40 mIU/mL).   FSH test willbe performed centrally.
I1F-MC-RHBQ Clinical Protocol Page 95
LY2439821Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research ph ysician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma -glutamyl 
transferase; CPK = creatine phosphokinase; IgG = immunoglobulin G; IgM = immunoglobulin M; INR = 
internatio nal no rmalized ratio; RBC =erythrocy te count; WBC = leukocytes .  
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
Leo Document ID = b605f0be-e97f-4c97-a836-f6936e647b36
Approver: 
Approval Date & Time: 14-Nov-2015 00:12:19 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 14-Nov-2015 01:14:30 GMT
Signature meaning: Approved
PPD
PPD